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Human papillomavirus (HPV) is a common sexually transmitted disease which
infects various sites in the body including the genitals, oral cavity, and anal regions.
Very little research has assessed the prevalence of concurrent and concordant high risk
(HR) HPV oral and genital infections in the general United States population despite
the fact that HR HPV oral pharyngeal cancers are on the rise in the US, particu-
larly in men. To further our understanding of HR HPV concurrent and concordant
infections we aim to estimate the prevalence of HR HPV concurrent and concordant
infections in the U.S. population, and for men and women separately. The next aim is
to determine via Monte Carlo simulations, whether HR HPV concurrent and concor-
dant infections happen more than expected by chance, given the population marginal
rates of oral and genital infections. Lastly, we characterize predictors of HR HPV
concurrent and concordant infections. We use the cross-sectional National Health
and Nutrition Examination Survey (NHANES). Participants included women from
NHANES 2009-2014 and men from NHANES 2013-2014 who had valid HPV test re-
sults. Concurrent infections were identified in 116 (2.5%) individuals in the combined
population (65 (4.0%) men and 51 (.76%) women). Simulations showed that the ob-
served prevalence of concurrent infections exceeded the expected prevalence for the
combined population, men, and women (1.13%, 4.0%, and .76%, respectively). Simi-
larly, we identified concordant infections in 59 (.99%) of individuals (29 (1.5%) men
and 30 (.47%) women). Simulations showed that the observed prevalence of concor-
dant infections exceeded the expected prevalence for the combined population, men,
and women (.15%, .26%, and .05% respectively). Our multivariable analysis for men
showed marital status, lifetime number of sexual partners, lifetime number of oral
sex partners, recent number of oral sex partners, marijuana use, and sexual orienta-
tion were all positively associated with HR HPV concurrent infection, and lifetime
number of sex partners, recent number of sex partners, and sexual orientation were
positively associated with HR concordant infections. Our multivariable analysis for
women showed no predictors were associated with HR HPV concurrent infections, and
cigarette use was positively associated with HR HPV concordant infections. Impor-
tantly, our analyses show that HR HPV infections between the oral and genital sites
are not independent of one another. We further highlight several factors that are im-
portant predictors of HR HPV concurrent and concordant infections. These analyses
show the importance of the HPV vaccine and suggest its continued recommendation,
perhaps more adamantly in boys and men than previously suggested.
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1 Introduction
1.1 Public Health Significance
Human papillomavirus (HPV) is one of the most common sexually transmitted dis-
eases in the United States [1]. The most common anatomical sites for HPV infection
are the anogenital and upper aerodigestive tract. There are over 100 types of HPV
that are categorized either into high-risk HPV (HR HPV) types, which are known
to have oncogenic potential, or low risk types. There are 18 HPV types which are
classified as HR and include types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58,
59, 66, 68, 73, and 82 [2]. Persistent HR HPV infection is known to cause cancer
at several anatomic sites including cervical, vulvar, vaginal, oropharyngeal, anal, and
penile cancers [3]. The causal effect of HPV on cervical cancers is well known and
studied. It is estimated that 90-99% of cervical cancer cases are attributable to HPV
[4, 5]. Between 2004-2008 and 2008-2012 there has been a decrease in the average rate
of cervical carcinoma diagnosed each year in the United States, likely due to improved
screening and HPV testing in women; however, the overall rate of HPV-associated
cancer has increased during this same time period [6].
A portion of the observed increase in HPV-associated cancers is possibly due to
the increasing incidence of HPV positive oropharyngeal cancers (OPC). OPCs include
“cancers of the base of the tongue, pharyngeal tonsils, anterior and posterior tonsillar
pillars, and glosstonsillar sulci; anterior surface of soft palate and uvula; and lateral
and posterior pharyngeal walls” [6]. While oral HPV infections are relatively rare, the
incident rate of HPV-associated OPC in women and men is about six and 38 times
larger than HPV-associated anal cancer, respectively, and the incidence of HPV-
associated OPC in men is 9.5 times larger than penile cancers [3, 6]. Between 1988
and 2004, the incidence of HPV-negative OPC declined by 50%, while the incidence
of HPV-positive OPC increased by 225% leading to an overall increase of 28% in the
incidence of OPC [7]. It was also estimated that the annual number of HPV-associated
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OPC would surpass the annual number of HPV-associated cervical cancers by 2020 if
these trends continue; however, this happened between 2008 and 2012 [6, 7]. Another
study estimated that the rate of HPV-associated OPC has increased in the United
States by 2.5% per year on average between 2002 and 2012 [8]. It is estimated that
of all OPC approximately 70% are associated with HPV [7, 5]. Several studies have
reported that men are disproportionately infected; rates for OPCs in men is about 4
times higher than that of women [3, 6, 8, 9]. In addition to this, several studies from
other countries have also reported increasing incidence of HPV-associated cancers in
men including OPC [8].
The high rate of cervical cancers and increasing rates of OPC that are associated
with HPV are of concern in light of current HPV vaccine uptake trends, particularly
in men. The Advisory Committee on Immunization Practices has recommended vac-
cination for girls aged 11 or 12 years since 2006, and for boys since 2011 [10]. For
vaccinations initiated between ages 9 and 14 years, a two-dose series is recommended,
while for those initiated between ages 15 and 26 years, a three-dose series is rec-
ommended [10]. All of the available vaccines target HPV 16 and 18, the two most
common HPV types found in HPV-associated cancers causing 63% of cases [6]. The
bivalent vaccine protects against types 16 and 18, the quadrivalent which adds cover-
age for types 6 and 11 responsible for most genital warts, and the nine-valent which
adds coverage for five additional HR HPV types, 31, 33, 45, 52, and 58. It is estimated
that vaccines targeting HPV types 16 and 18 could potentially prevent almost 25,000
cases of cancer annually in the United States and that the nine-valent vaccine could
potentially prevent almost an additional 4,000 cases annually [5]. Despite the bene-
fits, the rates of vaccination are relatively low when compared with other 3-dose series
vaccinations. In the United States, of females age 13 to 17 years old in 2016, 65.1%
received one or more doses, 55.0% received two or more doses, 43.0% received three or
more doses, and for males the rates were 56.0%, 43.6%, and 31.5%, respectively [11].
For comparison, in the case of the Hepatitis B vaccine, 94.1% of adolescent males had
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received three or more doses [11].
Given the well-known oncogenic potential of HR HPV and the dearth of research
on quantifying infections in both the oral and genital cavity, this thesis will quantify
and characterize concurrent and concordant HR HPV infections in the U.S. population
[12, 13, 2, 6]. Concurrent HPV infection is defined as simultaneous detection of any
HR HPV genotype in both the genitals and the oral cavity of a person. Concordant
HPV infection is defined as one or more of the same HR HPV genotypes detected in
both the genital and the oral cavity of a person. Any HPV infection is defined as an
infection with either a low-risk or high-risk HPV type.
1.2 Background
Currently, little is known about HR HPV concurrent and concordant oral and genital
HPV infections in the United States’ general population. There have been a few
studies on concurrent and concordant infections – one for men and one for women in
the United States’ general population both using the National Health and Nutrition
Examination Survey (NHANES) data, and one for men in a rural China population
that quantified concurrent and concordant HPV infections with any type (though not
specifically HR) [14, 15, 16]. None of these studies performed any further analysis
on the HR HPV type subgroup, which are responsible for the majority of cancers
described above. Additionally, another study quantified and analyzed concurrent
infections in men and women in the United States using NHANES data, but did not
necessarily break down those infections by HR and non-HR, perhaps due to small
sample sizes [12].
The single study of concurrent and concordant infections with any HPV in U.S.
men using NHANES found the prevalence of genital, oral, concurrent, and concordant
HPV infection with any type (including low risk) to be 45.3%, 11.2%, 8.8%, and 3.2%,
respectively [16]. This study also showed that the prevalence of oral HPV was much
higher in men that had a genital infection than among those that had no genital
3
infection, 19.3% and 4.4%, respectively [16]. The authors also found that lifetime
number of any sex (oral, vaginal, or anal) and recent number of any sex partners
(number of any sex partners in previous 12 months) was associated with concurrent
and concordant infections [16]. One issue with this study, due to sample size, is
that not all of the covariates could be included in one multivariable model; therefore,
several models were created which all included age, race/ethnicity, smoking status,
and one additional covariate based on participant sexual behavior.
The study on concurrent and concordant infections with any HPV in U.S. women
using NHANES found the prevalence of genital, oral, concurrent, and concordant
HPV infection with any type to be 45.2%, 4.1%, 3.0%, and 1.1%, respectively [15].
The study also showed that the prevalence of concurrent (genital) infection for women
with an oral infection was 75.9% and the prevalence of concurrent (oral) infection for
women with a genital infection was 6.8%, which is less than that found for men in
the aforementioned study [15]. The authors also found age was associated with both
concurrent and concordant infections, number of recent oral sex partners is associated
with concurrent infection, performing oral sex with a new partner in the past year
is associated with concordant infection, and increasing income to poverty ratio was
negatively associated with concurrent and concordant infection.
Other studies have also shown a difference in the prevalence of oral HPV infection
between men and women, as found in the two previous studies described. In a study
of U.S. men and women that focused on oral HPV infections using NHANES, the
prevalence of any oral HPV was 11.5% in men and 3.2% in women and the prevalence
of HR oral HPV was significantly higher in men than women at 7.3% and 1.4%,
respectively [12]. This study also looked at concurrent oral genital infections and
found the prevalence of any HPV oral infection among men with any HPV genital
infection and HR HPV oral infections among men with any HPV genital infection to
be 19.3% and 13.7%, respectively, where the prevalence of any HPV and HR HPV
oral infection among men without a genital infection was 4.4% and 3.9%, respectively
4
[12]. Similarly, the prevalence of any HPV oral infection among women with any
HPV genital infection and HR HPV oral infections among women with any HPV
genital infection was 5.1% and 3.2%, respectively, where the prevalence among women
without a genital infection was 2.1% and 1.1%, respectively [12]. It was also shown
that gender, race/ethnicity, cigarette use, and lifetime number of oral sex partners
were associated with concurrent HPV infections of any type [12].
The population study on concurrent and concordant HPV infection in men of rural
China showed the prevalence of genital, oral, and concurrent HPV77 infection with
any type to be 16.9%, 6.7% and 1.9%, respectively, and the prevalence of any oral
HPV among men with and without a genital infection was 11.4% and 5.7%, respec-
tively. Among the men that had a concurrent infection, 62.8% also had a concordant
infection [14]. This group also performed a Monte-Carlo simulation which showed that
the number of observed concordant infections greatly exceeded the expected number.
However, since this study population was from rural China, the results are not gen-
eralizable as sexual practices in this population are known to be more conservative
[14]. While this Chinese study very thoroughly quantified and analyzed concordant
and concurrent HR HPV subtypes, it suffers from a small sample size due to the fact
that it is not nationally representative of China (the population in this study is a
rural one).
The unique opportunity to quantify and analyze concordance and concurrence
over multiple years up through 2014 in a nationally representative U.S. sample is the
novelty of this thesis. To this end, we aim to fill in the gaps in knowledge that the
aforementioned papers could not or did not address; namely, we quantify and analyze
HR HPV concurrent and concordant infections in a U.S. representative sample. The
distinction between HR HPV and low-risk HPV that some of the prior research did
not make (potentially due to small sample sizes for the HR groups) is a lost oppor-
tunity. The distinction is incredibly important from a public health standpoint due
to the carcinogenic potential of the HR types. Additionally, we determine whether
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HR concurrent and concordant HPV infections are occurring more than expected by
random chance. We use the NHANES data set (2013-2014 for men and 2009-2014 for
women) which is particularly useful for addressing these questions due to it being a
nationally representative survey.
1.3 Specific Aims
1.3.1 Characterize the national prevalence of, and predictors of, high-
risk HPV concurrent and concordant infections using NHANES,
and relevant subgroups of high-risk HPV types
Although there have been several studies of concurrent and concordant oral and genital
HPV infections, there is still a gap in the knowledge, presumably due to sample
size limitations or non-representativeness of prior studies. For example, none of the
previous studies analyzed only the subgroup of HR HPV infections, which are the
HPV types that are attributable to HPV-related cancers and thus are the greatest
public health burden. Using NHANES years 2013-2014 for men and 2009-2014 for
women gave us the statistical power to focus solely on the high-risk subtypes. Using
the NHANES study, we estimated the overall prevalence of HR HPV concurrent and
concordant infections as well as concurrent and concordant infections for three relevant
sub-groupings of HR HPV, i.e., the HR HPV types covered in the 9-valent vaccine,
the three most common HPV types in HPV-associated cancers, HPV 16, 18, and 45,
and HPV 16 which is the most common type found in HPV-associated cancers. We
then built adjusted logistic regression models to determine the predictors that are
associated with overall HR HPV concurrent and concordant infections.
1.3.2 Determine whether high risk concurrent and concordant HPV in-
fections are more prevalent than expected by chance
Using the results from Aim 1, we performed Monte-Carlo simulations to determine
(a) whether the observed prevalence of overall HR HPV concurrent infections and (b)
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whether the three subgroups of HR HPV are greater than that expected by chance.
Similarly, we used Monte Carlo simulations to determine whether the observed preva-
lence of overall HR HPV concordant infections is greater than that expected by chance.
Determining whether concurrent and concordant infections are occurring more fre-
quently than expected will clarify the relationship between genital and oral HR HPV
infections from an epidemiological perspective. It will also lend insights to the natural
history of HPV infections and HPV transmission dynamics.
2 Methods
2.1 Study Design
For this study we used the NHANES data from 2009-2014 (for which oral HPV data
are available). NHANES is freely available for public health research through the Cen-
ters for Disease Control and Prevention. As the data are public and fully de-identified
, its use does not require institutional review board approval. Briefly, NHANES is
a series of cross-sectional 2-year surveys that are designed to assess the health and
nutrition of children and adults in the United States [1]. NHANES is designed to be
nationally representative of the resident, civilian, non-institutionalized United States
population living in the 50 states and District of Columbia [1]. Participants of the
survey completed questionnaires administered at home as well as completed a stan-
dardized health exam in a Mobile Examination Center (MEC) [1]. In order for there
to be a sample sufficient for subgroup analysis, certain demographics are over-sampled
including persons age 60 years and older, African Americans, Asians, and Hispanics
[1]. The NHANES data collection has been approved through the National Center
for Health Statistics Ethics Review Board. The survey uses a complex, multistage,
probability sampling design with differential probabilities of selection, and all analyses
must take the sample design into account using the sampling weights and sampling
design parameters [1].
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The data were downloaded from the NHANES website. At the time of this study,
oral and genital HPV genotypic data were available in the 2013-2014 NHANES cycle
for men and in the 2009-2010, 2011-2012, and 2013-2014 NHANES cycles for women.
Since we used multiple cycles of NHANES, new sample weights were computed follow-
ing the methods outlined in the NHANES weighting module [1]. In short, to create
new sample weights for data sets using multiple cycles of NHANES, one must divide
the provided weights by the number of cycles being used. Since for men there was
only one cycle of NHANES that has oral and genital HPV data, we used the provided
sample weights. For women, there were three NHANES cycles with oral and genital
HPV data available; therefore, six-year sample weights were created by dividing the
provided sample weights by three. Where possible, all analyses were performed taking
into account the survey weights and the sampling design in accordance the NHANES
guidelines, and all variance estimates were calculated using Taylor series lineariza-
tion. Estimates with a relative standard error less than 30% are considered unstable
and should be interpreted with caution. This study was limited to participants in
the publicly available NHANES data who also had valid oral and genital HPV test
results. Thus, this limited the study population to men and women age 18-59 years
old.
2.2 Specimen Collection and Laboratory Methods
The NHANES procedure for collection and laboratory methods are outlined in detail
elsewhere [1]. Briefly, oral samples were collected by having participants rinse and
gargle with Scope mouthwash [1]. Next, the samples were sent to Ohio State Univer-
sity Gillison Laboratory [1]. Once there, the samples were purified and analyzed for
37 types of HPV using a multiplex polymerase chain-reaction (PCR) assay [1]. Gen-
ital samples were collected by using self-collected vaginal and penile swabs collected
at the MEC [1]. The samples were processed at the Chronic Viral Diseases Branch
of the CDC using a Roche Linear Array HPV Genotyping test for the same 37 types
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of HPV as the oral samples [1]. All oral and genital samples that tested positive for
β-globin were considered to be of valid quality for analysis [1]. Of the 37 types of
HPV tested for, 18 of them are classified as HR HPV types including types 16, 18,
26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82 [2]. These 18 types
were used to determine the prevalence of overall HR HPV concurrent and concordant
infections. Additionally, three other subgroups of HR HPV were considered, HR HPV
types which are covered in the 9-valent HPV vaccine (types 16, 18, 31, 33, 45, 52, and
58), the three most common types found in HPV-associated cervical cancers (types
16, 18, and 45), and the most common type in all HPV-associated cancers (HPV 16)
[17, 18].
2.3 Methods: Aim 1
2.3.1 Estimate the national prevalence of HR HPV concurrent and con-
cordant infections
In order to estimate the overall prevalence of HR HPV concurrent infections, we first
identified subjects with a HR HPV oral infection and those with HR HPV genital
infections. Using this information, a two-way table was created using weighed cross
tabulation while taking into account the complex survey design. This led to tables of
prevalence estimates for HR HPV oral, genital, and concurrent infections. An odds
ratio was computed which is interpreted as the odds of a HR HPV oral infection given
that an individual has a HR HPV genital infection versus the odds of a HR HPV
oral infection given that an individual does not have a HR HPV genital infection.
The calculated OR was compared to 1 using McNemar’s Chi-square test. Similarly,
for the subgroups of HR HPV genotypes outlined above, the same procedure was
followed. This resulted in a total of four tables, each of which has the prevalence
estimates for oral, genital, and concurrent infections for overall HR HPV, HR 9-valent
vaccine type, HPV 16, 18, and 45, and HPV 16. This process was repeated for the
combined men and women populations, as well as and the men and women populations
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independently, resulting in 12 two-way tables. Calculation of the McNemar’s test used
the sample weights without the full NHANES design elements (cluster and strata), as
there is currently no statistical method available for this.
Similarly, for HR HPV concordant infections, we identified all subjects with a
HR HPV oral infection and those with a HR HPV genital infection. Next, we de-
termined which HR types were at the two anatomical locations and compared them.
Individuals were defined as having a HR HPV concordant infection if there was at
least one HR HPV type in common between the two sites. Once these individuals
were identified, the prevalence of HR HPV concordant infection in the population
was estimated taking into account the complex survey design and survey weights. In
addition to the overall prevalence of HR HPV concordant infection, we also estimated
the prevalence of HR HPV concordant infection among individuals who were positive
for HR HPV concurrent infection by limiting the analysis to individuals with a HR
HPV concurrent infection. We summarized the results in tables of individuals with
concordant infections who show complete (oral HR types exactly match genital HR
types) and partial (one or more HR types match between oral and genital sites, but
not all match) concordance and the HR HPV types at each anatomic site.
2.3.2 Characterize predictors of HR HPV concurrent and concordant in-
fections
2.3.2.1 Demographic and behavioral predictors to be included in analysis
Predictors included in the analysis were based on those previously shown to be
associated with concurrent, concordant, oral, or genital infections. Demographic pre-
dictors included race/ethnicity, gender, age group, and marital status; behavioral
predictors included number of lifetime any sex (oral, vaginal, and anal sex) partners,
number of recent (in the previous 12 months) any sex partners, number of lifetime
oral sex partners, number of recent oral sex partners, received HPV vaccine, cigarette
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use, marijuana use, and sexual orientation [16, 15, 12, 14, 13, 19, 20]. We coded
Race/ethnicity as non-Hispanic white, non-Hispanic black, and other race; gender as
male and female; age group as 18 to 24, 25 to 39, 40 to 59; marital status as mar-
ried, no longer married (includes widowed, divorced, and separated), never married,
living with partner, and missing; and lifetime number of any sex partners as 0-1, 2-5,
6-10, 11 or more, and missing. Due to a small sample size for men and the fact oral
and penile HPV were only recorded in the 2013-2014 cycle, coding of covariates had
to reflect categories with reasonable representation. Thus, we combined lifetime sex
partners 0-1 and 2-5; in regards to number of recent sex partners, we coded lifetime
number of oral sex partners, and number of recent oral sex partners as 0-1, 2-5, 6
or more, and missing; receiving HPV vaccine as yes, no, and missing; cigarette use
and marijuana use as never, ever, and missing; sexual orientation as heterosexual,
homosexual/bisexual, and other/missing.
2.3.2.2 Demographic and behavioral predictors tables for HR HPV con-
current and concordant infections
We present a table of demographic and behavioral predictors comparing the preva-
lence of each predictor in those with and without HR HPV concurrent infection. The
columns of each predictor sum to 100% so that the distribution of a predictor could
be compared between individuals with and without HR HPV concurrent infections.
We calculated the prevalence estimates taking into account the full survey design and
estimated 95% confidence intervals for the prevalence using the logistic method. This
method fits a logistic regression model and computes a Wald-type interval on the log-
odds scale, that is then transformed to the probability scale. Additionally, chi-square
test statistics were computed for each predictor using the Rao & Scott correction,
which adjusts for the Pearson chi-square statistic by a design effect estimate and then
compares it to the chi-square distribution it would have under simple random sam-
pling. All chi-square statistics were considered significant if the p-value was less than
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.05. Additionally, chi-square statistics with the p-values between (.05, .01], (.01, .005],
and those less than .005 were identified separately. Tables for the demographic and
behavioral predictors were created using the same methods for HR HPV concordant
infections. Lastly, we produced the HR HPV concurrent and concordant infection
tables for men and women combined, as well as for men and women separately.
2.3.2.3 Logistic regression models for HR HPV concurrent and concor-
dant infections Survey weighted logistic regression models were constructed for
both HR HPV concurrent and concordant infections to test the association between
demographic and behavioral predictors within the outcome. All testing was done us-
ing a two-sided test with a significance level of .05. All associations were reported
using odds ratios and estimates with p-values between (.05, .01], (.01, .005]. Those
less than .005 were identified separately. First, we conducted a univariate analysis
of demographic and behavioral predictors using survey weighted logistic regression
models to account for the complex survey design. This was followed by an adjusted
logistic regression analysis. All adjusted models included ethnicity, age, and gender,
when appropriate, as well as predictors which had a category in univariate analysis
with a p-value less than .15. Since we only used one NHANES cycle for men, we were
not able to run one adjusted logistic model because there were not enough degrees of
freedom to include all the predictors selected from the univariate model. As a result,
multiple models were created for men which included ethnicity, age group, marital
status, and one additional predictor at a time, which had a category in univariate
analysis with a p-value that was less than .15. The precedent for this approach to
analysis with NHANES when there is insufficient data can be found in Patel et al
[16].
12
2.4 Methods: Aim 2
2.4.1 Determine whether HR HPV concurrent infection is more prevalent
than expected by chance
Unlike other studies, we hypothesized and tested via simulation that the prevalence of
concurrent infections in men and women (separately and combined) would be greater
than that expected by chance. In order to determine if HR HPV concurrent infec-
tion was more prevalent than expected by chance, the prevalence estimates for HR
HPV oral and genital infections from Aim 1 were used in a Monte Carlo simulation
holding each prevalence estimate (genital and oral) constant. A population of 10,000
individuals and their HR HPV oral and genital status were simulated. HR HPV oral
and genital status were simulated using binomial distributions with the probability
of infection equal to the estimated prevalence of HR HPV oral and genital infections
in the population, respectively. We calculated the prevalence of HR HPV concurrent
infection in the simulated population and compared it to the observed prevalence
of HR HPV concurrent infection. This process was repeated 10,000 times, and the
expected prevalence was calculated by taking the average of these estimates. The p-
values comparing the expected and observed prevalence estimates were calculated by
counting the number of simulated HR HPV concurrent infection prevalence estimates
which were smaller than the observed prevalence in the population and dividing by the
total number of simulations. The simulated proportions were also used to calculate
the 95% confidence interval for the simulated proportion by taking the 2.5 and 97.5
percentiles of the simulated proportions. We repeated this for the four groups of HR
HPV infection, all HR HPV types, HR 9-valent vaccine types, HPV 16, 18, and 45,
and HPV 16, in the combined population as well as for men and women separately.
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2.4.2 Determine whether HR HPV concordant infection is more prevalent
than expected by chance
To determine if HR HPV concordant infection is more prevalent than expected by
chance, we applied a Monte Carlo simulation similar to the above. First, we esti-
mated the prevalence of oral and genital infections for each of the 18 HR HPV types.
A population of 10,000 individuals and their HR HPV type specific oral and genital
status was simulated. HR HPV Type specific oral and genital status was simulated
by binomial distributions where the probability of infection for a specific type at a
particular anatomic site is equal to the prevalence of that type in the specified location
in the population. The prevalence of HR HPV concordance of the simulated popula-
tion was calculated by identifying the proportion simulated subjects who had at least
one HR HPV type in common between both oral and genital sites. This process was
repeated 10,000 times, and a p-values and 95% confidence intervals were calculated in
the same way as outlined above. This was done for the combined population of men
and women as well as men and women separately.
3 Results
3.1 Aim 1
3.1.1 National prevalence of HR HPV concurrent and concordant infec-
tions
The estimated prevalence results for HR HPV concurrent infections are summarized
in Table 1. The estimated prevalence of overall HR HPV concurrent infection in the
United States total population, men, and women was 2.4% (n=116, 95% CI=(1.7,
3.3)), 4.0% (n=65, 95% CI=(2.7, 5.9)), and 0.76% (n=51, 95% CI=(0.52, 1.1)), re-
spectively. For the combined population, the prevalence of a HR HPV oral infections
among individuals with versus without a HR HPV genital infection was 8.7% and
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2.4%, respectively, and the prevalence of HR HPV genital infections among individu-
als with versus without a HR HPV oral infection was 57.2% and 26.0%, respectively.
For men, the prevalence of a HR HPV oral infections among men with versus without
a HR HPV genital infection was 13.7% and 3.9%, respectively, and the prevalence of
HR HPV genital infections among men with versus without a HR HPV oral infec-
tion was 59.4% and 27.1%, respectively. For women, the prevalence of a HR HPV
oral infections among women with versus without a HR HPV genital infection was
3.0% and 1.1%, respectively, and the prevalence of HR HPV genital infections among
individuals with versus without a HR HPV oral infection was 47.9% and 24.9%, re-
spectively. The odds of a HR HPV oral infection for those with versus without a HR
HPV genital infection for the total population, men, and women was 3.81 (McNe-
mar p-value < .005), 3.93 (McNemar p-value < .005), and 2.77 (McNemar p-value <
.005), respectively. The estimated prevalence of HR 9-valent vaccine type HPV con-
current infection in the United States total population, men, and women was 0.70%
(n=33, 95% CI=(0.41, 1.2)), 1.1% (n=17, 95% CI=(0.58, 2.3)), and 0.27% (n=16,
95% CI=(0.15, 0.49)), respectively. The odds of a HR 9-valent vaccine type HPV
oral infection for those with versus without a HR 9-valent vaccine type HPV genital
infection for the total population, men, and women was 4.79 (McNemar p-value <
.005), 4.5 (McNemar p-value < .005), and 5.31 (McNemar p-value < .005), respec-
tively. The estimated prevalence of a concurrent HPV 16, 18, or 45 infection in the
United States total population, men, and women was 0.37% (n=23, 95% CI=(0.20,
0.68)), 0.51% (n=11, 95% CI=(0.22, 1.2)), and 0.22% (n=12, 95% CI=(0.10, 0.49)),
respectively. The odds of an HPV 16, 18, or 45 oral infection for those with versus
without a HPV 16, 18, or 45 genital infection for the total population, men, and
women were 5.3 (McNemar p-value < .005), 4.18 (McNemar p-value < .005), and
10.57 (McNemar p-value < .005), respectively. The estimated prevalence of HPV
16 concurrent infection in the United States total population, men, and women was
0.16% (n=12, 95% CI=(0.08, 0.32)), 0.18% (n=6, 95% CI=(0.07, 0.47)), and 0.13%
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(n=6, 95% CI=(0.05, 0.35)), respectively. The odds an HPV 16 oral infection for
those with versus without an HPV 16 genital infection for the total population, men,
and women were 4.28 (McNemar p-value < .005), 2.6 (McNemar p-value < .005), and
16.16 (McNemar p-value < .005), respectively.
The estimated prevalence results for HR HPV concordant infections are summa-
rized in Tables 2 and 3. The estimated prevalence of HR HPV concordant infec-
tion in the United States total population, men, and woman was 0.99% (n=59, 95%
CI=(0.66, 1.5)), 1.5% (n=29, 95% CI=(0.88, 2.6)), and 0.47% (n=30, 95% CI=(0.31,
0.74)), respectively. The estimated prevalence of HR HPV concordant infection among
individuals that have a HR HPV concurrent infection in the United States total pop-
ulation, men, and women was 41.6% (n=59, 95% CI=(31.2, 52.8)), 37.6% (n=29, 95%
CI=(25.4, 51.6)), and 62.6% (n=30, 95% CI=(47.2, 75.8)), respectively.
3.1.2 Characterization of demographic and behavioral predictors of HR
HPV concurrent and concordant infections
3.1.2.1 Summary of demographic and behavioral predictors HR HPV
concurrent infections
Demographic and behavioral characteristics for HR HPV concurrent infections
for all three populations are further summarized in Tables 4 through 6. A total of
7010 individuals were tested for both genital and oral HPV infections of which 116
individuals were identified as having a HR HPV concurrent infection. The ethnic
distribution of individuals with HR HPV concurrent infection was 59 white (72.7%),
28 black (16.0%), and 29 other (11.3%) and the distribution of those without HR
HPV concurrent infection was 2,713 white (62.3%), 1,483 black (12.2%), and 2,698
other (25.5%). Ethnicity showed a significant association with HR HPV concurrent
infection with a chi-square p-value < .005. The distribution for age group among
individuals with a HR HPV concurrent infection was 29 in the 18 to 24 age group
(16.2%), 40 in the 25 to 39 age group (35.2%), and 47 in the 40 to 59 age group
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(48.7%), and for those without a HR HPV concurrent infection, it was 1,375 in the
18 to 24 age (17.5%), 2,373 in the 25 to 39 age group (34.8%), and 3,146 in the 40
to 59 age group (47.7%). Age group did not show a significant association with HR
HPV concurrent infection. Of the participants with a HR HPV concurrent infection
and those without there were 65 males (84.0%), and 51 females (16.0%) and 1,618
males (48.9%), and 5,276 females (51.1%), respectively. Gender was shown to be
significantly associated with HR HPV concurrent infection with a chi-squared p-value
< .005.
A total of 1,683 men were tested for both genital and oral HPV infections. The
ethnic distribution of men with a HR HPV concurrent infection was 38 white (75.4%),
18 black (16.0%), and 9 other (8.6%) and those without were 653 white (61.7%),
330 black (11.5%), and 635 other (26.8%). For men, ethnicity was also significantly
associated with HR HPV concurrent infections with a chi-squared p-value < .005.
The distribution of age among men with a HR HPV concurrent infection was 14 in
the 18 to 24 age group (15.0%), 24 in the 25 to 39 age group (36.1%), and 27 in the 40
to 59 age group (48.9%) and those without was 337 in the 18 to 24 age group (18.3%),
565 in the 25 to 39 age group (35.4%), and 716 in the 40 to 59 age group (46.3%).
Age was not significantly associated with HR HPV concurrent infection in men.
A total of 5,327 women were tested for both genital and oral HPV infections.
The ethnic distribution of women with a HR HPV concurrent infection was 21 white
(58.6%), 10 black (16.2%), and 20 other (25.2%), and those without was 2,060 white
(62.9%), 1,153 black (12.9%), and 2,063 other (24.2%). There was not a significant
association between HR HPV concurrent infections and ethnicity in women. The
distribution of age among women with a HR HPV concurrent infection was 15 in the
18 to 24 age group (22.4%), 16 in the 25 to 39 age group (30.1%), and 20 in the 40 to
59 age group (47.5%). For those without was 1,038 in the 18 to 24 age group (16.7%),
1,808 in the 25 to 39 age group (34.3%), and 2,430 in the 40 to 59 age group (49.0%).
There was not a significant association between HR HPV concurrent infection and
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age for women.
3.1.2.2 Summary of demographic and behavioral predictors HR HPV
concordant infections
Demographic and behavioral characteristics for HR HPV concordant infections
for all three populations are further summarized in Tables 4 through 6. A total of
7,010 individuals were tested for both genital and oral HPV infections of which 59
individuals were identified as having a HR HPV concordant infection. The ethnic dis-
tribution of individuals with a HR HPV concordant infection was 32 white (71.1%),
12 black (16.5%), and 15 other (12.4%). The distribution of those without HR HPV
concordant infection was 2,740 white (62.5%), 1,499 black (12.3%), and 2,712 other
(25.3%). There was not a significant association between HR HPV concordant infec-
tion and ethnicity. The distribution for age group among individuals with a HR HPV
concordant infection was 19 in the 18 to 24 age group (22.8%), 19 in the 25 to 39 age
group (41.9%), and 21 in the 40 to 59 age group (35.3%). For those without a HR
HPV concordant infection, it was 1,385 in the 18 to 24 age group (17.4%), 2,394 in the
25 to 39 age group (34.7%), and 3,172 in the 40 to 59 age group (47.9%). Age group
did not show a significant association with HR HPV concordant infection. Of the
participants with a HR HPV concordant infection and those without there were 29
males (75.9%), and 30 females (24.1%), and 1,654 males (49.5%), and 5,297 females
(50.5%), respectively. Gender was shown to be significantly associated with HR HPV
concordant infection with a chi-squared p-value < .005.
The ethnicity distribution of men with a HR HPV concordant infection was 38
white (75.4%), 18 black (16.0%), and 9 other (8.6%) and those without were 653
white (61.7%), 330 black (11.5%), and 635 other (26.8%). For men, ethnicity was
significantly associated with HR HPV concordant infections with a chi-squared p-
value < .05. The distribution of age among men with a HR HPV concordant infection
was 8 in the 18 to 24 age group (21.0%), 12 in the 25 to 39 age group (48.5%), and 9
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in the 40 to 59 age group (30.5%) and those without was 343 in the 18 to 24 age group
(18.2%), 577 in the 25 to 39 age group (35.2%), and 734 in the 40 to 59 (46.7%). Age
did not show a significant association with HR HPV concordant infection in men.
The ethnicity distribution of women with a HR HPV concordant infection was 15
white (69.6%), 4 black (8.3%), and 11 other (22.2%) and those without was 2,066 white
(62.8%), 1,159 black (13.0%), and 2,072 other (24.2%). There was not a significant
association between HR HPV concordant infections and ethnicity in women. The
distribution of age among women with a HR HPV concordant infection was 11 in the
18 to 24 age group (28.4%), 7 in the 25 to 39 age group (21.2%), and 12 in the 40 to 59
age group (50.4%) and for those without was 1,042 in the 18 to 24 age group (16.7%),
1,817 in the 25 to 39 age group (34.3%), and 2,438 in the 40 to 59 age group (49.0%).
There was not a significant association between HR HPV concordant infection and
age for women.
3.1.3 Logistic regression models for HR HPV concurrent and concordant
infection
3.1.3.1 Univariable logistic regression models for HR HPV concurrent
infection
The results of the univariable logistic regression models for HR HPV concurrent
infections for the combined population, men, and women are provided in Tables 7
through 9. Due to issues of singularity in the multivariable models, all participants
with missing data for the sexual history questions were removed from the models
(n=609). After removing them, there were no longer any participants with HR HPV
concurrent or concordant infections in the missing category for marijuana use in the
combined population, men, and women, and, thus, this category was removed from
analysis as well (n=14). Additionally, there were no longer any women with HR
HPV concurrent or concordant infection in the missing category for HPV vaccination
status, and this level was dropped from the women models only (n=148).
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For the combined population in the univariate logistic models, there were only a
few variables (age group, HPV vaccination status, and cigarette use) which showed
no statistically significant association with HR HPV concurrent infections. All other
predictors had at least one category which showed a significant association with HR
HPV concurrent infection. In regards to ethnicity, both white and black individuals
showed a significant positive association with HR HPV concurrent infection compared
to the other ethnicity. For gender, females showed a significant negative association
with HR HPV concurrent infection compared to males. For marital status, no longer
married, never married, and living with partner showed a significant positive associa-
tion with HR HPV concurrent infection compared to married individuals. For lifetime
number of sex partners, individuals with 6-10 and 11+ partners showed a significant
positive association with HR HPV concurrent infections compared to those with 0-1
partners. For recent number of sex partners, individuals with 2-5 and 6+ partners
showed a significant positive association with HR HPV concurrent infection compared
to those with 0-1 partners. For lifetime oral sex partners, individuals with 6+ partners
showed a significant positive association with HR HPV concurrent infection compared
to those with 0-1 partners. For recent number of oral sex partners, individuals with
2-5 and 6+ partners showed significant positive associations with HR HPV concur-
rent infection compared to those with 0-1 partners. For marijuana use, individuals
who had ever used marijuana showed a significant positive association with HR HPV
concurrent infections compared to those who had never used marijuana. For sexual
orientation, individuals who identified as homosexual or bisexual showed a significant
positive association with HR HPV concurrent infection compared to heterosexuals.
Age group, HPV vaccination status, and cigarette use showed no statistically sig-
nificant association with HR HPV concurrent infections in men. For ethnicity, both
white and black men showed a significant positive association with HR HPV concur-
rent infection compared to the other ethnicity. For marital status, no longer married,
never married, and living with partner showed a significant positive association with
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HR HPV concurrent infection compared to married men. For lifetime number of sex
partners, men with 6-10 and 11+ partners showed a significant positive association
with HR HPV concurrent infections compared to those with 0-5 partners. For recent
number of sex partners, men with 2-5 and 6+ partners showed a significant positive
association with HR HPV concurrent infection compared to those with 0-1 partners.
For lifetime oral sex partners, men with 6+ partners showed a significant positive as-
sociation with HR HPV concurrent infection compared to those with 0-1 partners. For
recent number of oral sex partners, men with 2-5 and 6+ partners showed significant
positive associations with HR HPV concurrent infection compared to those with 0-1
partners. For marijuana, use men who had ever used marijuana showed a significant
positive association with HR HPV concurrent infections compared to those who had
never used marijuana. For sexual orientation, men who identified as homosexual or
bisexual showed a significant positive association with HR HPV concurrent infection
compared to heterosexuals.
Ethnicity, age group, HPV vaccination status, and sexual orientation showed no
statistically significant association with HR HPV concurrent infections in women.
For marital status, no longer married, never married, and women with missing data
showed a significant positive association with HR HPV concurrent infection compared
to married women. For lifetime number of sex partners, women with 11+ partners
showed a significant positive association with HR HPV concurrent infections compared
to those with 0-1 partners. For recent number of sex partners, women with 2-5
and 6+ partners showed a significant positive association with HR HPV concurrent
infection compared to those with 0-1 partners. For lifetime oral sex partners, women
with 6+ partners showed a significant positive association with HR HPV concurrent
infection compared to those with 0-1 partners. For recent number of oral sex partners,
women with 2-5 and 6+ partners showed significant positive associations with HR
HPV concurrent infection compared to those with 0-1 partners. For cigarette use,
women who had ever smoked and those with missing data both showed a significant
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positive association with HR HPV concurrent infection compared to those who had
never smoked cigarettes. For marijuana use, women who had ever used marijuana
showed a significant positive association with HR HPV concurrent infections compared
to those who had never used marijuana.
3.1.3.2 Multivariable logistic regression models for HR HPV concurrent
infection
The multivariable logistic models were created using covariates that had at least
one category which was significant in addition to ethnicity, age group, and gender,
where appropriate. For the combined population this included ethnicity, gender,
age group, marital status, lifetime number of sex partners, recent number of sex
partners, lifetime number oral partners, recent number of oral partners, marijuana
use, and sexual orientation. Covariates which were significant in the multivariable
logistic regression model of HR HPV concurrent infection for the combined population
included gender and lifetime number of sex partners. For gender, females showed a
significant negative association with HR HPV concurrent infection compared to males
(OR = 0.25; 95% CI = (0.15, 0.42); p-value < .005). For lifetime number of sex
partners, the groups 6-10 and 11+ showed a significant positive association with HR
HPV concurrent infection compared to individuals with 0-1 partners (OR = 5.5; 95%
CI = (1.5, 20.7); p-value < .05, and OR = 16.7; 95% CI = (4.0, 69.9); p-value < .005,
respectively).
The covariates used for the multivariable logistic models for men included ethnic-
ity, age group, marital status, lifetime number of sex partners, recent number of sex
partners, lifetime number of oral sex partners, recent number of oral sex partners,
marijuana use, and sexual orientation. As stated in the methods section, there were
not enough degrees of freedom to run a single multivariable model due to a lack of
sample size. Therefore, multiple models were run, all of which include ethnicity, age
group, marital status in addition to one other covariate. Covariates which were signif-
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icant in the multivariable logistic regression models included marital status, lifetime
number of sex partners, lifetime number of oral partners, recent oral partners, mar-
ijuana use, and sexual orientation. For marital status, men who were never married
showed a significant positive association with HR HPV concurrent infection compared
to married men (OR = 2.6; 95% CI = (1.3, 5.5); p-value < .05). For lifetime num-
ber of sex partners, men with 6-10 and 11+ partners showed a positive association
with HR HPV concurrent infection compared to men with 0-5 partners (OR = 5.0;
95% CI = (1.7, 14.6); p-value < .05, and OR = 27.8; 95% CI = (7.8, 98.5); p-value
< .005, respectively). For lifetime number of oral partners, men with 6+ partners
showed a significant positive association with HR HPV concurrent infection com-
pared to those with 0-1 partners (OR = 10.8; 95% CI = (3.3, 34.9); p-value < .05).
For recent number of oral sex partners, men with 2-5 partners showed a significant
positive association with HR HPV concurrent infection compared to men with 0-1
partners (OR = 2.8; 95% CI = (1.6, 4.9); p-value < .05). For marijuana use, men
who had ever used marijuana showed a significant positive association with HR HPV
concurrent infections compared to those who had never used marijuana (OR = 2.8;
95% CI = (1.3, 6.1); p-value < .05). For sexual orientation homosexual and bisex-
ual men showed a significant positive association with HR HPV concurrent infection
compared to heterosexuals (OR = 4.2; 95% CI = (1.6, 11.2); p-value < .05).
For women, the multivariable logistic regression model ethnicity, age group, mar-
ital status, lifetime number of sex partners, recent number of sex partners, lifetime
number of oral sex partners, recent number of oral sex partners, cigarette use, and
marijuana use were all included in the model. In this adjusted model, none of the
covariates showed a statistically significant association with HR HPV concurrent in-
fections.
3.1.3.3 Univariable logistic regression models for HR HPV concordant
infection
23
The results of the univariable logistic regression models for HR HPV concordant
infections for the combined population, men, and women are provided in Tables 7
through 9. For the combined population in the univariable logistic models age group,
HPV vaccination status, and marijuana use showed no statistically significant as-
sociation with HR HPV concordant infections. All other predictors had at least
one category which showed a significant association. For ethnicity, black individuals
showed a significant positive association with HR HPV concordant infection compared
to the other ethnicity. For gender, females showed a significant negative association
with HR HPV concordant infection compared to males. For marital status, no longer
married and never married showed a significant positive association with HR HPV
concordant infection compared to married individuals. For lifetime number of sex
partners, individuals with 6-10 and 11+ partners showed a significant positive associ-
ation with HR HPV concordant infections compared to those with 0-1 partners. For
recent number of sex partners, individuals with 2-5 and 6+ partners showed a signifi-
cant positive association with HR HPV concordant infection compared to those with
0-1 partners. For lifetime oral sex partners, individuals with 6+ partners showed a
significant positive association with HR HPV concordant infection compared to those
with 0-1 partners. For recent number of oral sex partners, individuals with 2-5 and 6+
partners showed significant positive associations with HR HPV concordant infection
compared to those with 0-1 partners. For cigarette use, individuals that had ever
smoked cigarettes showed a significant positive association with HR HPV concordant
infection compared to those who never smoked cigarettes. For sexual orientation,
individuals who identified as homosexual or bisexual showed a significant positive
association with HR HPV concordant infection compared to heterosexuals.
For men, age group, HPV vaccination status, cigarette use, and marijuana use
showed no statistically significant association with HR HPV concordant infections.
For ethnicity, black men showed a significant positive association with HR HPV con-
cordant infection compared to the other ethnicity. For marital, status never married
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men showed a significant positive association with HR HPV concordant infection
compared to married men. For lifetime number of sex partners, individuals with 11+
partners showed a significant positive association with HR HPV concordant infections
compared to those with 0-5 partners. For recent number of sex partners, men with 2-5
and 6+ partners showed a significant positive association with HR HPV concordant
infection compared to those with 0-1 partners. For lifetime oral sex partners, men
with 6+ partners showed a significant positive association with HR HPV concordant
infection compared to those with 0-1 partners. For recent number of oral sex part-
ners, men with 2-5 and 6+ partners showed significant positive associations with HR
HPV concordant infection compared to those with 0-1 partners. For sexual orien-
tation, men who identified as homosexual or bisexual showed a significant positive
association with HR HPV concordant infection compared to heterosexuals.
For women ethnicity, HPV vaccination status, and sexual orientation showed no
statistically significant association with HR HPV concordant infections. Age group
25-39 years showed a significant negative association with HR HPV concordant infec-
tions compared to the 18-24 age group. For marital status, women with missing data
showed a significant positive association with HR HPV concordant infection compared
to married women. For lifetime number of sex partners, women with 11+ partners
showed a significant positive association with HR HPV concordant infections com-
pared to those with 0-1 partners. For recent number of sex partners, women with 2-5
and 6+ partners showed a significant positive association with HR HPV concordant
infection compared to those with 0-1 partners. For lifetime oral sex partners, women
with 6+ partners showed a significant positive association with HR HPV concordant
infection compared to those with 0-1 partners. For recent number of oral sex part-
ners, women with 2-5 and 6+ partners showed significant positive associations with
HR HPV concordant infection compared to those with 0-1 partners. For cigarette use,
women who had ever smoked and those with missing data both showed a significant
positive association with HR HPV concordant infection. For marijuana use, women
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who had ever used marijuana showed a significant positive association with HR HPV
concordant infections compared to those who had never used marijuana.
3.1.3.4 Multivariable logistic regression models for HR HPV concordant
infection
The multivariate logistic models for HR HPV concordant infection were created
using covariates which had at least one category which was significant in addition to
ethnicity, age group, and gender, where appropriate. For the combined population,
the covariates included in the model were ethnicity, gender, age group, marital status,
lifetime number of sex partners, recent number of sex partners, lifetime number of oral
sex partners, recent number of oral sex partners, cigarette use, and sexual orientation.
Covariates which were significant in the combined population multivariable model for
HR HPV concordant infection were gender and lifetime number of sex partners. For
gender, females showed a significant negative association with HR HPV concordant
infection compared to males (OR = 0.35; 95% CI = (0.16, 0.78); p-value < .05).
For lifetime number of sex partners, the groups 6-10 and 11+ showed a significant
positive association with HR HPV concordant infection compared to individuals with
0-1 partners (OR = 5.1; 95% CI = (1.3, 19.9); p-value < .05 and OR = 16.1; 95% CI
= (3.4, 75.5); p-value < .005, respectively).
The covariates used for the multivariable logistic models for HR HPV concordant
infection in men included ethnicity, age group, marital status, lifetime number of sex
partners, recent number of sex partners, lifetime number of oral sex partners, re-
cent number of oral sex partners, and sexual orientation. The same procedures were
used to create the HR HPV concordant multivariable models for men as in the HR
HPV concurrent multivariable models for men. Covariates which were significant in
the multivariable logistic regression models included lifetime number of sex partners,
recent number of sex partners, and sexual orientation. For lifetime number of sex
partners, men with 11+ partners showed a positive association with HR HPV concor-
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dant infection compared to men with 0-5 partners (OR = 11.1; 95% CI = (2.6, 46.6);
p-value < .05). For recent number of sex partners, men with 2-5 partners showed a
significant positive association with HR HPV concordant infection compared to those
with 0-1 partners (OR = 2.7; 95% CI = (1.3, 5.6); p-value < .05). For sexual orien-
tation, men who identified as homosexual and bisexual showed a significant positive
association with HR HPV concordant infection compared to heterosexuals (OR = 8.5;
95% CI = (2.6, 27.2); p-value < .05).
The covariates used in the multivariable logistic models for HR HPV concordant
infection in women included ethnicity, age group, marital status, lifetime number of
sex partners, recent number of sex partners, lifetime number of oral sex partners,
recent number of oral sex partners, cigarette use, and marijuana use. Only cigarette
use showed a significant association with HR HPV concordant infection. Women who
had ever smoked cigarettes showed a positive association with HR HPV concordant
infections (OR = 3.3; 95% CI = (1.3, 8.1); p-value < .05).
3.2 Aim 2
3.2.1 Determine whether HR HPV concurrent infections are more preva-
lent than expected by chance
The results for all HR HPV concurrent infections can be found in Figures 1 through
3. The estimated prevalence of any HR HPV in the genital and oral cavity for the
combined population was 27.3% (95% CI: 25.9, 28.8) and 4.2% (95% CI: 3.3, 5.3),
respectively. These numbers were used to estimate the expected prevalence of any
HR HPV concurrent infections at 1.1% (95% CI: .93, 1.35), which were significantly
less than the observed prevalence (1.1% vs. 2.4%; p-value = 0). The estimated
prevalence of any HR HPV in the genital and oral cavity for men was 29.3% (95%
CI: 27.2, 31.6) and 6.7% (95% CI: 4.9, 9.1), respectively. These numbers were used
to estimate the expected prevalence of any HR HPV concurrent infections in men at
1.98% (95% CI: 0.0171, 0.0226), significantly less than the observed prevalence (1.98%
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vs. 4.0%; p-value = 0). The estimated prevalence of any HR HPV in the genital and
oral cavity for women was 25.3% (95% CI: 23.4, 27.3) and 1.6% (95% CI: 1.2, 2.1),
respectively. These numbers were used to estimate the expected prevalence of any HR
HPV concurrent infections in women at 0.40% (95% CI: 0.0028, 0.0053), significantly
less than the observed prevalence (0.40% vs. 0.76%; p-value = 0).
The estimated prevalence of HR 9-valent vaccine types in the genital and oral
cavity for the combined population was 12.2% (95% CI: 11.3, 13.2) and 1.8% (95% CI:
1.3, 2.5), respectively. These numbers were used to estimate the expected prevalence
of HR 9-valent vaccine type concurrent infections in the combined population at 0.22%
(95% CI: 0.0013, 0.0032), significantly less than the observed prevalence (0.22% vs.
0.70%; p-value = 0). The estimated prevalence of HR 9-valent vaccine types in the
genital and oral cavity for men was 13.0% (95% CI: 11.6, 14.5) and 3.0% (95% CI:
2.0, 4.4), respectively. These numbers were used to estimate the expected prevalence
of HR 9-valent vaccine type concurrent infections in men at 0.39% (95% CI: 0.0027,
0.0052), significantly less than the observed prevalence (0.39% vs. 1.1%; p-value = 0).
The estimated prevalence of HR 9-valent vaccine types in the genital and oral cavity
for women was 11.4% (95% CI: 10.2, 12.7) and 0.67% (95% CI: 0.43, 1.0), respectively.
These numbers were used to estimate the expected prevalence of HR 9-valent vaccine
type concurrent infections in women at 0.08% (95% CI: 0.0003, 0.0014), significantly
less than the observed prevalence (0.08% vs. 0.27%; p-value = 0).
The estimated prevalence of HPV 16, 18, or 45 in the genital and oral cavity for
the combined population was 7.2% (95% CI: 6.4, 8.0) and 1.3% (95% CI: 0.90, 1.9),
respectively. These numbers were used to estimate the expected prevalence of HPV 16,
18, or 45 concurrent infections in the combined population at 0.09% (95% CI: 0.0004,
0.0016) and were significantly less than the observed prevalence (0.09% vs. 0.37%;
p-value = 0). The estimated prevalence of HPV 16, 18, or 45 in the genital and oral
cavity for men was 7.6% (95% CI: 6.4, 9.0) and 2.1% (95% CI: 1.3, 3.3), respectively.
These numbers were used to estimate the expected prevalence of HPV 16, 18, or 45
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concurrent infections in men at 0.16% (95% CI: 0.0009, 0.0024), significantly less than
the observed prevalence (0.16% vs. 0.51%; p-value = 0). The estimated prevalence of
HPV 16, 18, or 45 in the genital and oral cavity for women was 6.7% (95% CI: 5.8, 7.8)
and 0.51% (95% CI: 0.29, 0.90), respectively. These numbers were used to estimate the
expected prevalence of HPV 16, 18, or 45 concurrent infections in women at 0.03%
(95% CI: 0.0000, 0.0008) and were significantly less than the observed prevalence
(0.03% vs. 0.22%; p-value = 0).
The estimated prevalence of HPV 16 in the genital and oral cavity for the combined
population was 4.0% (95% CI: 3.4, 4.8) and 1.0% (95% CI: 0.75, 1.5), respectively.
These numbers were used to estimate the expected prevalence of HPV 16 concurrent
infections in the combined population at 0.04% (95% CI: 0.0001, 0.0009) and were
significantly less than the observed prevalence (0.04% vs. 0.16%; p-value = .0001).
The estimated prevalence of HPV 16 in the genital and oral cavity for men was 4.4%
(95% CI: 3.3, 5.8) and 1.8% (95% CI: 1.2, 2.6), respectively. These numbers were used
to estimate the expected prevalence of HPV 16 concurrent infections in men at 0.08%
(95% CI: 0.0003, 0.0014), also significantly less than the observed prevalence (0.08%
vs. 0.18%; p-value = .0004). The estimated prevalence of HPV 16 in the genital and
oral cavity for women was 3.7% (95% CI: 3.0, 4.5) and 0.34% (95% CI: 0.19, 0.63),
respectively. These numbers were used to estimate the expected prevalence of HPV
16 concurrent infections in women at 0.01% (95% CI: 0.0000, 0.0004), significantly
less than the observed prevalence (0.01% vs. 0.13%; p-value = 0).
3.2.2 Determine whether HR HPV concordant infections are more preva-
lent than expected by chance
The estimated prevalence HR HPV of genital and oral infections by HPV subtypes
for the combined population can be found in Figure 4. These estimates were used to
calculate the expected prevalence of HR HPV concordant infections for the combined
population at .15% (95% CI: 0.08, 0.23). The expected prevalence was significantly
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less than the observed prevalence (.15% vs. 0.99%; p-value = 0). The estimated
prevalence HR HPV of genital and oral infections by HPV subtypes for men can be
found in Figure 5. These estimates were used to calculate the expected prevalence of
HR HPV concordant infections for men at .26% (95% CI: 0.17, 0.37). The expected
prevalence was significantly less than the observed prevalence (.15% vs. 1.5%; p-value
= 0). Additionally, the estimated prevalence HR HPV of genital and oral infections
by HPV subtypes for women can be found in Figure 6. These estimates were used
to calculate the expected prevalence of HR HPV concordant infections for women at
.05% (95%CI: 0.01, 0.11). The expected prevalence was significantly less than the
observed prevalence (.05% vs. .47%; p-value = 0).
4 Discussion
Currently, research on HPV concurrent and concordant infections is limited, and, to
our knowledge, this is the first study to focus solely on HR HPV type concurrent
and concordant infections in the general United States population in both men and
women. This study estimates that 2.4% of the combined population has a HR HPV
concurrent infection and 0.99% have a HR HPV concordant infection. Using the
2010 census population, this equates to an estimated 7.4 million Americans with
HR HPV concurrent infections and 3.1 million with HR HPV concordant infections.
Based on the estimates of HR HPV concurrent and concordant infections for men,
4.0% and 1.5%, respectively, this is about 6.1 million men with HR HPV concurrent
infections and 2.3 million men with HR HPV concordant infections. Similarly, the
estimates of HR HPV concurrent and concordant infections for women, .76% and
.47%, respectively, equates to 1.2 million women with HR HPV concurrent infections
and 700,000 women with HR HPV concordant infections. Also of interest is the
number of HR 9-valent vaccine type concurrent infections in the population which
have an estimated prevalence of 1.1% and .27% for men and women, respectively.
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This amounts to about 1.7 million men and just over 400,000 women who have a HR
9-valent vaccine type concurrent infection that could potentially have been prevented
by the HPV 9-valent vaccine.
Several studies have shown that individuals with an infection at one anatomic
location are more likely to have an infection at the other site. Kedarisetty et al
showed that for any HPV type, 6.8% of women with a vaginal HPV infection had
an oral HPV infection while 1.0% of women with no vaginal HPV infection had an
oral HPV infection [15]. Similarly, 75.9% of women with an oral HPV infection had
a vaginal HPV infection while 42.2% of woman with no oral HPV infection had a
vaginal HPV infection [15]. Patel et al found similar results for any HPV type in men
with 19.3% of men with a penile HPV infection had an oral HPV infection while 4.4%
of men with no penile HPV infection had an oral HPV infection [16]. Additionally,
Sonawane et al showed similar associations for oral HPV infections between both men
and women with and without genital HPV infections [12]. This is consistent with our
results which showed for the combined population, men, and women of individuals
with a HR HPV genital infection versus those without are more likely to have a HR
HPV oral infection; similarly, those with a HR HPV oral infection are more likely to
have a HR HPV genital infection versus those without a HR HPV oral infection.
Additionally, the results of our simulations further support the notion that geni-
tal and oral HPV infections are not independent of one another. These simulations
show what the expected prevalence of HR HPV concurrent genital and oral infections
would be if they were occurring at random given the rates of genital and oral HR
HPV infection in the population. For all three populations and four subgroups of
HR HPV analyzed, the observed rate of HR HPV concurrent infection was signifi-
cantly higher than the expected rate. In most cases the observed rate of HR HPV
concurrent infections was two to four times higher than the expected rate. Similar
results were shown for the rates of HR HPV concordant infections as well, with the
observed rate being about 7, 6, and 9 times greater than the expected rate for the
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combined population, men, and women, respectively. Despite the fact that HR HPV
concurrent infections are relatively rare, the rates of HR HPV concordant infection
were quite high particularly in women (41.6%, 37.6%, and 62.6% for the combined
population, men, and women, respectively). These simulation results were similar to
those in a study of concurrent and concordant infections with any type of HPV in
a rural Chinese population [14]. Overall, these results could have important clinical
implications and, as suggested by Kedarisetty et al, serve as the basis for increased
screening of individuals known to have an HPV infection at 1 anatomic site [15].
Currently there is no protocol for HPV positive OPC screening, and these findings
suggest that increased screening for OPC in individuals known to have a HR HPV
genital infection is warranted [15]. Conversely, individuals diagnosed with HPV as-
sociated OPCs should be more closely monitored for genital infections and cancers,
since persons known to have a HR HPV oral infection are much more likely to have
a HR HPV genital infection than those without an oral infection [15].
In the United States, rates of any HPV in the genitals are known to be similar for
men and women, while for any HPV and HR HPV oral infection rates were higher in
men than women 11.5% and 3.2% and 7.3% and 1.4%, respectively [16, 15, 12]. We
found similar results, with rates of genital HR HPV infections being similar between
men and women for the four groups of HR HPV analyzed, all HR, HR 9-valent vaccine
types, HPV 16, 18, and 45, and HPV 16, while the rates of oral infections for these
four groupings of HR HPV were four to five times higher in men than in women. It
is not known why the rates of oral HPV infection are higher in men than women,
but theories include that men have more sexual partners than women, transmission
of HPV is more efficient when performing oral sex on infected females compared
to infected males, and women may have partial systematic immunity from cervical
infections that protect them against oral HPV infections, which men do not [3]. Given
that rates of genital HPV infections are similar between men and women and that oral
HPV is much more common in men, it is not surprising that rates of concurrent and
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concordant HR HPV infections were also higher among men. For all HR HPV types
the rate of concurrent infection is significantly different between men and women,
approximately 5-fold greater in men. Similar results were seen for the HR 9-valent
vaccine types with the rate in men being 4 times that of women. While the rates of
concurrent infections for the other groupings of HPV, types 16, 18, or 45, and HPV
16, were higher in men than women, the differences were not statistically significant.
We found a similar result for HR HPV concordant infections with the rate being
about 3 times higher in men than in women which was statistically significant. These
differences in HR HPV concurrent and concordant infections between men in women
are consistent with two studies analyzing any HPV concurrent and concordant in-
fections between men and women separately [16, 15]. In one study of United States
men, the prevalence of any HPV concordant infection among those with any HPV
concurrent infection (note this includes low and high-risk HPV) was 36.2% [16]. In
a study of men in rural China, the same prevalence was 62.8% [14]. Although our
population is quite different from that of rural Chinese men, our results showed a
prevalence of HR HPV concordant infection among men with a HR HPV concurrent
infection of about 38%, i.e., closer to findings in the U.S. study. To our knowledge,
this has not been previously examined in women, yet we found a prevalence of HR
HPV concordant infection among women with a HR HPV concurrent infection was
nearly 63%. A higher rate of HR HPV concordant infections among women with
HR HPV concurrent infection is a particularly interesting result considering that HR
HPV concurrent and concordant infections are much more common in men; however,
this difference was not statistically significant. The three most common HR types
detected in HR HPV concordant infections were HPV 16, 59, and 51 for both men
and women.
For the combined population many of the predictors showed a significant associ-
ation with HR HPV concurrent and concordant infections in the univariate analysis
with the exception of age, HPV vaccine, and cigarette use (for HR HPV concurrent
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infections only). It is not very surprising that HPV vaccination status was not as-
sociated with HR HPV concurrent and concordant infections considering that the
vaccine has only been recommended since 2006 for women and 2011 for men [10].
Also, HPV vaccination status has been shown to not be associated with any HPV
concurrent or concordant infections in women as well as not being associated with
oral HPV infections in both men and women [15, 12]. It is a little surprising that
age was not associated with HR HPV concurrent or concordant infections since age
is associated with genital and oral HPV infection in men and women independently
[12, 13, 21]. However, this association might not be apparent given our relatively
small sample size. In the adjusted models, the only covariates that remained signifi-
cant for both HR HPV concurrent and concordant infections were gender and lifetime
number of sexual partners. These results are not surprising considering the differ-
ence in prevalence of HR HPV concurrent and concordant infections between men
and women. Additionally, lifetime number of sex partners is associated with genital
and oral HPV infections in men and women; thus, this result is not surprising either
[12, 13, 21]. Typically, in HPV studies men and women are analyzed separately; thus,
to our knowledge there are no similar results to compare to. However, in light of our
small sample size, we feel this analysis could be informative in addition to the results
of analyzing men and women separately.
Our analysis of men showed that the lifetime number of sex partners was posi-
tively associated with HR HPV concurrent and concordant infections, similar to what
has been shown in another study investigating any HPV concurrent and concordant
infections [16]. We found homosexual/bisexual men were more likely to have HR
HPV concurrent and concordant infections, not surprising since homosexual/bisexual
men have been shown to have higher rates of oral HPV infection [12]. We also found
positive associations between HR HPV concurrent infections and 6+ lifetime number
of oral sex partners and 2-5 recent oral sex partners, also consistent with a prior U.S.
study by Patel et al [16]. However, these associations were not present with HR HPV
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concordant infections, in contrast to Patel et al, who found an association with any
HPV concordant infections [16]. These authors also observed that never married men
were more likely to have a HR HPV concurrent infection compared to married men,
but this was not observed in rural Chinese men nor in our results of HR HPV concur-
rent infections [14]. Men who had ever used marijuana showed a positive association
with HR HPV concurrent, but not concordant, infection. Marijuana use has also been
shown to be associated with oral HPV infection in men [12]. Men with 2-5 recent sex
partners showed a positive association with HR HPV concordant infection, similar to
what was found in the study by Patel et al. However, we did not find an association
with HR HPV concurrent infection and recent number of sex partners as they did
[16].
Ethnicity was associated with HR HPV concurrent and concordant infections in
the univariate analysis for men. However, this association was attenuated in both of
the adjusted models for HR HPV concurrent and concordant infections, similar to
that found in Patel et al [16]. Covariates that showed no association with HR HPV
concurrent and concordant infections in the univariate analysis for men included age,
HPV vaccination status, and cigarette use. Age was still included in the adjusted
models and did not show a significant association with HR HPV concurrent or con-
cordant infections similar to the results of the study of any HPV concurrent and
concordant infections in men [16]. Cigarette use has been associated with oral HPV
infections in men; however, two other studies found no association with HR HPV
concurrent infections, one of which also showed cigarette use is not associated with
HR HPV concordant infections [16, 12, 14].
Based on our results for men, lifetime number of sex partners, lifetime number of
oral sex partners, recent number of oral sex partners, marijuana use, sexual orienta-
tion, and marital status play an important role in HR HPV concurrent infections and
should be considered when talking with patients about HPV infections. Additionally,
lifetime number of sex partners, recent number of sex partners, and sexual orienta-
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tion are significant predictors of HR HPV concordant infections and should also be
considered when counseling patients.
Results for women revealed that none of our covariates were associated HR HPV
concurrent infections in the adjusted model. This differs from what was shown in a
previous NHANES study of any HPV concurrent infections in women which showed
that age group was associated with any HPV concurrent infection [15]. This discrep-
ancy may be due to our smaller sample size or the fact that their adjusted models
were slightly different (e.g., they included poverty ratio, which was associated with
any HPV concurrent infections); we did not examine this. [15]. Our results showed
that lifetime number of sex partners and recent number of oral sex partners were not
associated with HR HPV concurrent infection, consistent with the results found in
the study of any HPV concurrent infection in women [15]. Additionally, recent num-
ber of any sex partners and lifetime number of oral sex partners were not associated
with HR HPV concurrent infection. These results were surprising considering that
all four of these covariates were associated with HR HPV concurrent infections in
the univariate analysis and are independently associated with oral and genital HPV
infections [12, 21]. Covariates associated with HR HPV concurrent infection in the
univariate analysis included marital status, cigarette use, and marijuana use, similar
to what has been found for oral and genital HPV infections independently, but these
associations were also attenuated in the adjusted model [12, 21]. Similar to men, HPV
vaccination status was not associated with HR HPV concurrent infections in women,
nor were sexual orientation and ethnicity.
In women, a similar pattern was observed for HR HPV concordant and concurrent
HR HPV infections, with only cigarette use retaining a significant association with HR
HPV concordant infection in the adjusted model. This is different from the previous
study on any HPV concordant infection which found associations for age, a recent
number of oral sex partners. Again, this could be due to our smaller sample size
and different categorization of these variables [15]. Additionally, all of the sexual
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history questions showed significant associations with HR HPV concordant infections
in the univariate analysis, but were attenuated in the adjusted model. This result
is surprising considering that lifetime number of sex partners and recent number of
sex partners have been associated with genital and oral HPV infections, and lifetime
number of oral sex partners is associated with oral HPV infections [12, 21]. Age
group, marital status, and marijuana use were also significant in the univariate, but
not multivariate analysis. Age is also known to be associated with oral and genital
infections independently [12, 21]. Marital status is known to be associated with HPV
genital infections in women, and marijuana use is known to be associated with oral
HPV infection in women [12, 21].
HR HPV concurrent and concordant infections are relatively rare in the popula-
tion, and, thus, one of the major limitations of this study is a lack of sample size. Due
to this, many of the estimates in this study have a relative standard error less than
30% which the CDC warns may be unstable [1]. Additionally, with the small num-
ber of individuals with HR HPV concurrent and concordant infections, we may not
have the statistical power to detect associations which are actually there. Nonethe-
less, these are the data that are currently available and, to our knowledge, reflect the
largest population-based study of HR HPV concurrent and concordant infections to
date. This analysis should be repeated as more NHANES cycles become available to
provide more stable estimates and build a single multivariate model for men.
Other limitations of this study include the cross-sectional design of NHANES.
Therefore, temporal relationships between infections at different anatomic sites can-
not be established to further elucidate HPV infection natural history. Furthermore,
since there is no follow up, we cannot determine if these infections are incident infec-
tions, persistent infections, reinfection, or reactivation from latent infections. We also
cannot determine if these infections are clearing or developing into HPV-associated
cancers. Longitudinal studies are needed in order to address these types of ques-
tions. Additionally, individuals chose to answer sexual history questions, i.e., they
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reflect self-report, and are thus prone to reporting bias. Participants also chose to
participate in the HPV testing and therefore also subject to selection bias.
Regardless of these limitations, these results may have clinical significance in com-
bating HPV and HPV-associated cancers. They provide a possible foundation that
could guide clinicians in screening practices of HPV infections and HPV associated
cancers. Additionally, they indirectly highlight the importance of the HPV vaccine,
providing support for its continued recommendation, perhaps even more adamantly
considering how low the current vaccination rate is, to adolescents and individuals at
increased risk of HPV infection. This is especially true of men and boys, who have
been shown to have a much lower rate of vaccination rate, than women and girls [11].
The novelty of this study is conducting research that shows HR HPV concurrent and
concordant infections are happening more than expected. Additional investigation
using longitudinal studies is warranted to further elucidate the reasons.
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5 Tables and Figures
Table 1: Two-Way Prevalence Tables of High Risk (HR) Oral and Genital Human
Papillomavirus (HPV) for the Four Groups of HR HPV for the Combined Population,
Men, and Women. (U.S. National Health and Nutrition Examination Survey, 2013-
2014 for Men, 2009-2014 for Women)
Oral
Yes No Total
Genital n Percent(95% CI) n Percent(95% CI) n Percent(95% CI)
Combined
HR HPV
Yes 116 2.4(1.7, 3.3) 1863 24.9(23.5, 26.4) 1979 27.3(25.9, 28.8)
No 94 1.8(1.2, 2.6) 4937 70.9(69.1, 72.7) 5031 72.7(71.2, 74.1)
Total 210 4.2(3.3, 5.3) 6800 95.8(94.7, 96.7) 7010
HR 9V Types
Yes 33 0.70(0.41, 1.2) 875 11.5(10.6, 12.4) 908 12.2(11.3, 13.2)
No 48 1.1(0.69, 1.8) 6054 86.7(85.7, 87.7) 6102 87.8(86.8, 88.7)
Total 81 1.8(1.3, 2.5) 6929 98.2(97.5, 98.7) 7010
HPV 16, 18, 45
Yes 23 0.37(0.20, 0.68)^ 504 6.8(6.0, 7.8) 527 7.2(6.4, 8.0)
No 36 0.93(0.62, 1.4) 6447 91.9(91.1, 92.6) 6483 92.8(92.0, 93.6)
Total 59 1.3(0.90, 1.9) 6951 98.7(98.1, 99.1) 7010
HPV 16
Yes 12 0.16(0.08, 0.32)^ 255 3.9(3.2, 4.7) 267 4.0(3.4, 4.8)
No 31 0.89(0.58, 1.4) 6712 95.1(94.4, 95.7) 6743 96.0(95.2, 96.6)
Total 43 1.0(0.75, 1.5) 6967 99.0(98.5, 99.3) 7010
Men
HR HPV
Yes 65 4.0(2.7, 5.9) 432 25.3(23.3, 27.5) 497 29.3(27.2, 31.6)
No 48 2.7(1.6, 4.5) 1138 67.9(64.7, 71.0) 1186 70.7(68.4, 72.8)
Total 113 6.7(4.9, 9.1) 1570 93.3(90.9, 95.1) 1683
HR 9V Types
Yes 17 1.1(0.58, 2.3)^ 206 11.9(10.5, 13.3) 223 13.0(11.6, 14.5)
No 25 1.8(1.00, 3.3) 1435 85.2(83.4, 86.7) 1460 87.0(85.5, 88.4)
Total 42 3.0(2.0, 4.4) 1641 97.0(95.6, 98.0) 1683
HPV 16, 18, 45
Yes 11 0.51(0.22, 1.2)^ 121 7.1(5.8, 8.7) 132 7.6(6.4, 9.0)
No 19 1.6(0.95, 2.6) 1532 90.8(89.6, 91.9) 1551 92.4(91.0, 93.6)
Total 30 2.1(1.3, 3.3) 1653 97.9(96.7, 98.7) 1683
HPV 16
Yes 6 0.18(0.07, 0.47)^ 65 4.2(3.1, 5.7) 71 4.4(3.3, 5.8)
No 19 1.6(0.95, 2.6) 1593 94.1(92.7, 95.1) 1612 95.6(94.2, 96.7)
Total 25 1.8(1.2, 2.6) 1658 98.2(97.4, 98.8) 1683
Women
HR HPV
Yes 51 0.76(0.52, 1.1) 1431 24.5(22.7, 26.5) 1482 25.3(23.4, 27.3)
No 46 0.82(0.58, 1.2) 3799 73.9(71.9, 75.7) 3845 74.7(72.7, 76.6)
Total 97 1.6(1.2, 2.1) 5230 98.4(97.9, 98.8) 5327
HR 9V Types
Yes 16 0.27(0.15, 0.49)^ 669 11.1(9.9, 12.4) 685 11.4(10.2, 12.7)
No 23 0.40(0.23, 0.68) 4619 88.2(86.9, 89.4) 4642 88.6(87.3, 89.8)
Total 39 0.67(0.43, 1.0) 5288 99.3(99.0, 99.6) 5327
HPV 16, 18, 45
Yes 12 0.22(0.10, 0.49)^ 383 6.5(5.6, 7.5) 395 6.7(5.8, 7.8)
No 17 0.29(0.16, 0.56)^ 4915 93.0(91.9, 93.9) 4932 93.3(92.2, 94.2)
Total 29 0.51(0.29, 0.90) 5298 99.5(99.1, 99.7) 5327
HPV 16
Yes 6 0.13(0.05, 0.35)^ 190 3.6(2.9, 4.3) 196 3.7(3.0, 4.5)
No 12 0.22(0.10, 0.46)^ 5119 96.1(95.3, 96.8) 5131 96.3(95.5, 97.0)
Total 18 0.34(0.19, 0.63)^ 5309 99.7(99.4, 99.8) 5327
^ The relative standard error of the weighted prevalence estimate was >30%.
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Table 2: Estimated Prevalence of High Risk (HR) Concordant Human Papillomavirus
(HPV) infections for the Combined Population, Men, and Women (U.S. National
Health and Nutrition Examination Survey, 2013-2014 for Men, 2009-2014 for Women)
Combined Men Women
Concordance n Percent(95% CI) n Percent(95% CI) n Percent(95% CI)
Total Population
Concordant 59 0.99(0.66, 1.5) 29 1.5(0.88, 2.6) 30 0.47(0.31, 0.74)
Non-Concordant 57 1.4(0.94, 2.0) 36 2.5(1.6, 3.9) 21 0.28(0.18, 0.46)
No Concurrent 6894 97.6(96.7, 98.3) 1618 96.0(94.1, 97.3) 5276 99.2(98.9, 99.5)
Individuals with Concurrent Infection
Concordant 59 41.6(31.2, 52.8) 29 37.6(25.4, 51.6) 30 62.6(47.2, 75.8)
Non-Concordant 57 58.4(47.2, 68.8) 36 62.4(48.4, 74.6) 21 37.4(24.2, 52.8)
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Table 3: : Table of High Risk (HR) Human Papillomavirus (HPV) Types in Complete
and Partial HR HPV Concordant Infections (U.S. National Health and Nutrition
Examination Survey, 2013-2014 for Men, 2009-2014 for Women)
Concordance Type Genital Types Oral Types Count Concordance Type Genital Types Oral Types Count
Combined
Complete 16 16 6 Partial 35 35, 59 1
Complete 18, 51 18, 51 1 Partial 16, 39, 52, 66, 53 39 1
Complete 39, 66 39, 66 1 Partial 39 39, 53 1
Complete 45 45 2 Partial 39, 45 45 1
Complete 45, 68 45, 68 1 Partial 45, 59 45 1
Complete 51 51 3 Partial 51, 53 51 1
Complete 52 52 1 Partial 51, 58 51 1
Complete 53 53 2 Partial 51, 59, 26 51, 26 1
Complete 58 58 1 Partial 52, 53 52 1
Complete 59 59 5 Partial 31, 51, 53 53 1
Complete 68 68 1 Partial 51, 53 53 1
Complete 73 73 4 Partial 16, 35, 39, 51, 59, 66, 53 59 1
Partial 16, 18, 51, 66, 82 16 1 Partial 16, 59 59 1
Partial 16, 31, 51, 52, 56, 66, 53 16 1 Partial 16, 59, 53 59 1
Partial 16, 31, 56, 53 16 1 Partial 18, 51, 56, 59, 68 59 1
Partial 16, 39, 52 16 1 Partial 59, 82 59 1
Partial 16, 53 16 1 Partial 16, 39, 66 66 1
Partial 16, 82 16 1 Partial 18, 51, 66 66 1
Partial 18, 31, 45 18 1 Partial 51, 52, 66 66 1
Partial 16, 18, 51 18, 51 1 Partial 58, 66 66 1
Partial 16, 33, 59 18, 59 1 Partial 59, 73 73 1
Partial 35, 45, 52 35 1 - - - -
Concordance Type Genital Types Oral Types Count Concordance Type Genital Types Oral Types Count
Men
Complete 16 16 4 Partial 35 35, 59 1
Complete 45 45 1 Partial 16, 39, 52, 66, 53 39 1
Complete 51 51 2 Partial 39 39, 53 1
Complete 53 53 1 Partial 45, 59 45 1
Complete 59 59 2 Partial 51, 58 51 1
Complete 68 68 1 Partial 16, 35, 39, 51, 59, 66, 53 59 1
Complete 73 73 3 Partial 16, 59, 53 59 1
Partial 16, 31, 51, 52, 56, 66, 53 16 1 Partial 18, 51, 56, 59, 68 59 1
Partial 16, 53 16 1 Partial 16, 39, 66 66 1
Partial 16, 18, 51 18, 51 1 Partial 18, 51, 66 66 1
Partial 16, 33, 59 18, 59 1 Partial 58, 66 66 1
Concordance Type Genital Types Oral Types Count Concordance Type Genital Types Oral Types Count
Women
Complete 16 16 2 Partial 16, 82 16 1
Complete 18, 51 18, 51 1 Partial 18, 31, 45 18 1
Complete 39, 66 39, 66 1 Partial 35, 45, 52 35 1
Complete 45 45 1 Partial 39, 45 45 1
Complete 45, 68 45, 68 1 Partial 51, 53 51 1
Complete 51 51 1 Partial 51, 59, 26 51, 26 1
Complete 52 52 1 Partial 52, 53 52 1
Complete 53 53 1 Partial 31, 51, 53 53 1
Complete 58 58 1 Partial 51, 53 53 1
Complete 59 59 3 Partial 16, 59 59 1
Complete 73 73 1 Partial 59, 82 59 1
Partial 16, 18, 51, 66, 82 16 1 Partial 51, 52, 66 66 1
Partial 16, 31, 56, 53 16 1 Partial 59, 73 73 1
Partial 16, 39, 52 16 1 - - - -
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Table 4: Distribution of Predictors of High Risk Human Papillomavirus Concurrent
and Concordant Infections for Combined Population (U.S. National Health and Nu-
trition Examination Survey, 2013-2014 for Men, 2009-2014 for Women)
Concurrent Infection Concordant Infection
Concurrent Infection No Concurrent Infection Concordant Infection No Concordant Infection
Term N Percent(95% CI) N Percent(95% CI) N Percent(95% CI) N Percent(95% CI)
Ethnicity***
Other 29 11.3(6.3, 19.4) 2698 25.5(21.4, 30.1) 15 12.4(5.0, 27.6)^ 2712 25.3(21.2, 29.8)
White 59 72.7(61.1, 81.8) 2713 62.3(57.1, 67.2) 32 71.1(56.0, 82.7) 2740 62.5(57.3, 67.4)
Black 28 16.0(10.2, 24.3) 1483 12.2(9.9, 14.9) 12 16.5(9.2, 27.8) 1499 12.3(9.9, 15.0)
Gender***†††
Male 65 84.0(76.6, 89.4) 1618 48.9(46.1, 51.8) 29 75.9(61.9, 85.9) 1654 49.5(46.7, 52.4)
Female 51 16.0(10.6, 23.4) 5276 51.1(48.2, 53.9) 30 24.1(14.1, 38.1) 5297 50.5(47.6, 53.3)
Age Group
18 to 24 29 16.2(9.8, 25.6) 1375 17.5(15.9, 19.2) 19 22.8(13.1, 36.8) 1385 17.4(15.9, 19.1)
25 to 39 40 35.2(21.8, 51.4) 2373 34.8(33.1, 36.6) 19 41.9(21.1, 66.0) 2394 34.7(33.0, 36.6)
40 to 59 47 48.7(32.3, 65.3) 3146 47.7(45.5, 49.9) 21 35.3(17.8, 57.8) 3172 47.9(45.7, 50.0)
Marital Status***††
Married 24 23.1(13.7, 36.2) 3105 51.3(48.6, 54.1) 12 22.7(9.0, 46.7)^ 3117 50.9(48.2, 53.7)
No longer married 24 24.5(12.9, 41.7) 1031 12.7(11.6, 13.9) 12 21.3(9.1, 42.3)^ 1043 12.9(11.7, 14.1)
Never married 40 34.7(25.1, 45.9) 1611 22.7(20.5, 24.9) 20 38.6(25.1, 54.2) 1631 22.8(20.6, 25.2)
Living with partner 18 14.6(8.1, 25.1) 634 8.8(7.5, 10.2) 7 11.1(4.8, 23.5)^ 645 8.9(7.7, 10.3)
Missing 10 3.1(1.2, 7.4)^ 513 4.5(3.9, 5.2) 8 6.3(2.1, 17.2)^ 515 4.5(3.9, 5.2)
Lifetime Sex Partners***†††
0-1 7 1.3(0.50, 3.2)^ 1345 16.7(14.1, 19.7) 6 2.2(0.76, 6.4)^ 1346 16.5(13.9, 19.4)
2-5 18 7.3(3.2, 15.7)^ 2227 30.9(28.9, 32.9) 11 11.7(4.5, 27.1)^ 2234 30.5(28.5, 32.6)
6-10 23 11.0(5.9, 19.6) 1360 21.2(19.5, 22.9) 12 12.4(6.2, 23.4) 1371 21.0(19.4, 22.7)
11+ 61 72.8(58.8, 83.5) 1360 25.1(22.8, 27.5) 29 71.3(51.3, 85.4) 1392 25.8(23.6, 28.1)
Missing 7 7.6(2.5, 21.2)^ 602 6.1(5.4, 7.0) 1 2.3(0.23, 19.7)^ 608 6.2(5.5, 7.0)
Recent Sex Partners***†††
0-1 61 50.6(37.5, 63.7) 5217 78.0(75.7, 80.1) 32 48.5(33.7, 63.5) 5246 77.6(75.4, 79.7)
2-5 38 34.6(24.7, 46.1) 952 13.5(12.2, 14.9) 20 38.6(27.5, 50.9) 970 13.7(12.4, 15.2)
6+ 10 7.2(3.6, 13.6)^ 123 2.4(1.9, 3.2) 6 10.6(4.1, 24.6)^ 127 2.5(1.9, 3.2)
Missing 7 7.6(2.5, 21.2)^ 602 6.1(5.4, 7.0) 1 2.3(0.23, 19.7)^ 608 6.2(5.5, 7.0)
Lifetime Oral Partners***†††
0-1 20 7.9(3.8, 15.5)^ 2642 32.1(29.3, 35.0) 13 12.0(4.5, 28.2)^ 2649 31.7(28.9, 34.6)
2-5 35 18.9(14.3, 24.5) 2573 40.5(38.7, 42.4) 20 27.4(14.5, 45.6) 2588 40.1(38.3, 42.0)
6+ 54 65.6(56.7, 73.6) 1080 21.3(19.1, 23.7) 25 58.3(40.2, 74.4) 1109 22.0(19.8, 24.4)
Missing 7 7.6(2.5, 21.2)^ 599 6.1(5.3, 7.0) 1 2.3(0.23, 19.7)^ 605 6.2(5.5, 7.0)
Recent Oral Partners***†††
0-1 74 59.5(48.1, 69.9) 5650 84.1(82.5, 85.6) 36 57.3(39.7, 73.1) 5688 83.8(82.3, 85.2)
2-5 27 27.3(19.3, 37.1) 584 8.9(7.9, 10.0) 17 31.8(18.8, 48.4) 594 9.1(8.1, 10.2)
6+ 8 5.6(2.2, 13.6)^ 61 0.91(0.69, 1.2) 5 8.6(2.6, 25.3)^ 64 0.94(0.73, 1.2)
Missing 7 7.6(2.5, 21.2)^ 599 6.1(5.3, 7.0) 1 2.3(0.23, 19.7)^ 605 6.2(5.5, 7.0)
HPV Vaccine
Yes 17 6.4(3.2, 12.3)^ 663 7.3(6.4, 8.2) 9 7.8(3.0, 18.7)^ 671 7.2(6.4, 8.2)
No 97 92.4(85.5, 96.1) 5943 88.1(86.9, 89.2) 48 89.2(75.3, 95.7) 5992 88.2(87.0, 89.3)
Missing 2 1.2(0.25, 5.6)^ 288 4.6(3.9, 5.4) 2 2.9(0.53, 14.5)^ 288 4.6(3.9, 5.4)
Cigarette Use†††
Never 50 45.8(32.1, 60.2) 4204 58.2(55.7, 60.6) 22 36.8(21.5, 55.3) 4232 58.1(55.6, 60.5)
Ever 61 52.8(38.3, 66.9) 2464 40.6(38.1, 43.1) 33 60.4(41.4, 76.7) 2492 40.7(38.2, 43.2)
Missing 5 1.3(0.42, 4.2)^ 226 1.3(0.98, 1.6) 4 2.8(0.70, 10.6)^ 227 1.3(0.97, 1.6)
Marijuana Use***
Never 23 13.1(6.9, 23.5) 3102 37.9(35.2, 40.7) 14 21.7(9.0, 43.8)^ 3111 37.5(34.8, 40.3)
Ever 86 79.3(67.8, 87.4) 3189 55.8(53.0, 58.6) 44 75.9(58.1, 87.8) 3231 56.2(53.4, 59.0)
Missing 7 7.6(2.5, 21.2)^ 603 6.3(5.5, 7.1) 1 2.3(0.23, 19.7)^ 609 6.3(5.6, 7.1)
Sexual Orientation***†††
Heterosexual 93 77.0(64.5, 86.0) 5746 87.8(86.5, 89.0) 48 73.5(53.0, 87.2) 5791 87.7(86.4, 88.8)
Homosexual/Bisexual 13 14.7(7.0, 28.2)^ 337 4.2(3.6, 4.8) 7 22.4(9.5, 44.2)^ 343 4.2(3.6, 4.9)
Other 10 8.3(2.9, 22.0)^ 811 8.1(7.0, 9.2) 4 4.1(0.83, 17.9)^ 817 8.1(7.2, 9.1)
Concurrent Chi-Squared p-values:*P-Value < .05, **P-Value < .01, ***P-Value < .005; Concordant Chi-Squared p-values:†P-Value <
.05, ††P-Value < .01, †††P-Value < .005. ^ The relative standard error of the weighted prevalence estimate was >30%.
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Table 5: Distribution of Predictors of High Risk Human Papillomavirus Concurrent
and Concordant Infections for Men (U.S. National Health and Nutrition Examination
Survey, 2013-2014)
Concurrent Infection Concordant Infection
Concurrent Infection No Concurrent Infection Concordant Infection No Concordant Infection
Term N Percent(95% CI) N Percent(95% CI) N Percent(95% CI) N Percent(95% CI)
Ethnicity***†
Other 9 8.6(3.9, 17.9)^ 635 26.8(20.6, 34.1) 4 9.3(2.3, 30.4)^ 640 26.3(20.2, 33.5)
White 38 75.4(63.2, 84.5) 653 61.7(54.0, 68.9) 17 71.6(54.1, 84.4) 674 62.1(54.5, 69.2)
Black 18 16.0(9.5, 25.6) 330 11.5(8.5, 15.3) 8 19.1(9.9, 33.6) 340 11.6(8.5, 15.5)
Age Group
18 to 24 14 15.0(8.0, 26.4) 337 18.3(16.1, 20.8) 8 21.0(9.8, 39.4) 343 18.2(16.1, 20.4)
25 to 39 24 36.1(20.5, 55.3) 565 35.4(32.4, 38.5) 12 48.5(22.0, 75.8) 577 35.2(32.2, 38.3)
40 to 59 27 48.9(29.0, 69.1) 716 46.3(43.1, 49.5) 9 30.5(10.1, 63.1)^ 734 46.7(43.6, 49.7)
Marital Status***†
Married 15 23.9(13.3, 39.2) 765 52.4(48.1, 56.6) 5 22.3(7.1, 51.9)^ 775 51.7(47.4, 56.0)
No longer married 13 23.8(10.6, 45.0)^ 164 9.6(8.0, 11.3) 6 19.4(5.9, 48.0)^ 171 10.0(8.3, 12.0)
Never married 22 35.6(23.7, 49.5) 408 24.8(21.4, 28.6) 12 43.1(26.2, 61.7) 418 25.0(21.3, 29.0)
Living with partner 13 15.3(7.8, 27.9) 149 8.4(6.5, 10.8) 5 12.2(4.6, 28.9)^ 157 8.6(6.8, 10.9)
Missing 2 1.4(0.23, 8.4)^ 132 4.9(3.9, 6.0) 1 3.0(0.25, 27.3)^ 133 4.7(3.8, 5.8)
Lifetime Sex Partners***†††
0-5 4 3.1(0.95, 9.4)^ 692 42.2(37.0, 47.5) 4 8.2(2.1, 26.8)^ 692 41.1(36.0, 46.4)
6-10 10 8.4(3.7, 18.2)^ 314 20.8(18.4, 23.4) 3 7.2(3.0, 16.5)^ 321 20.5(18.2, 23.1)
11+ 47 80.3(65.7, 89.6) 517 32.6(28.4, 37.1) 21 81.6(62.0, 92.3) 543 33.8(29.7, 38.1)
Missing 4 8.2(2.3, 25.6)^ 95 4.4(3.3, 5.8) 1 3.1(0.25, 28.4)^ 98 4.6(3.6, 5.9)
Recent Sex Partners***†††
0-1 34 50.1(35.5, 64.6) 1193 76.4(72.3, 80.1) 14 47.0(30.2, 64.5) 1213 75.8(71.9, 79.3)
2-5 20 34.9(23.8, 48.0) 267 15.2(12.9, 17.8) 10 39.6(26.2, 54.8) 277 15.6(13.4, 18.2)
6+ 7 6.8(3.2, 13.7)^ 63 4.0(2.7, 5.8) 4 10.3(3.5, 26.8)^ 66 4.0(2.8, 5.8)
Missing 4 8.2(2.3, 25.6)^ 95 4.4(3.3, 5.8) 1 3.1(0.25, 28.4)^ 98 4.6(3.6, 5.9)
Lifetime Oral Partners***†††
0-1 7 5.6(1.9, 15.3)^ 562 29.8(25.4, 34.6) 5 11.6(3.0, 35.3)^ 564 29.1(24.8, 33.8)
2-5 14 15.0(9.6, 22.5) 587 39.3(36.4, 42.3) 6 20.9(6.6, 49.7)^ 595 38.6(35.7, 41.6)
6+ 40 71.3(62.4, 78.8) 374 26.5(23.3, 29.9) 17 64.4(41.0, 82.5) 397 27.7(24.5, 31.2)
Missing 4 8.2(2.3, 25.6)^ 95 4.4(3.3, 5.8) 1 3.1(0.25, 28.4)^ 98 4.6(3.6, 5.9)
Recent Oral Partners***†††
0-1 38 57.6(44.3, 69.9) 1336 84.1(81.6, 86.3) 15 54.5(31.0, 76.1) 1359 83.4(81.2, 85.5)
2-5 18 29.2(19.9, 40.8) 167 10.3(8.6, 12.4) 10 34.8(17.8, 56.8) 175 10.7(9.0, 12.7)
6+ 5 4.9(1.5, 14.7)^ 20 1.2(0.82, 1.8) 3 7.7(1.6, 29.7)^ 22 1.2(0.87, 1.8)
Missing 4 8.2(2.3, 25.6)^ 95 4.4(3.3, 5.8) 1 3.1(0.25, 28.4)^ 98 4.6(3.6, 5.9)
HPV Vaccine
Yes 5 4.4(1.5, 12.7)^ 69 3.8(2.9, 5.0) 3 6.8(1.3, 28.4)^ 71 3.8(3.0, 4.9)
No 58 94.1(85.2, 97.8) 1433 89.1(87.4, 90.5) 24 89.3(66.6, 97.2) 1467 89.3(87.6, 90.7)
Missing 2 1.4(0.28, 7.1)^ 116 7.1(5.8, 8.6) 2 3.9(0.62, 20.6)^ 116 6.9(5.6, 8.4)
Cigarette Use
Never 29 48.0(31.6, 64.9) 878 54.8(51.0, 58.6) 12 41.3(21.0, 65.0) 895 54.8(51.0, 58.5)
Ever 36 52.0(35.1, 68.4) 740 45.2(41.4, 49.0) 17 58.7(35.0, 79.0) 759 45.2(41.5, 49.0)
Marijuana Use**
Never 10 11.4(5.0, 24.1)^ 604 33.7(29.5, 38.1) 6 22.3(7.4, 50.9)^ 608 32.9(28.7, 37.4)
Ever 51 80.4(66.2, 89.5) 916 61.8(57.2, 66.1) 22 74.6(51.9, 88.9) 945 62.3(57.8, 66.6)
Missing 4 8.2(2.3, 25.6)^ 98 4.6(3.6, 5.9) 1 3.1(0.25, 28.4)^ 101 4.8(3.8, 5.9)
Sexual Orientation***†††
Heterosexual 51 75.2(60.1, 85.9) 1440 91.0(88.8, 92.8) 22 67.6(43.8, 84.9) 1469 90.7(88.5, 92.5)
Homosexual/Bisexual 9 16.0(7.0, 32.7)^ 48 3.0(2.1, 4.1) 5 27.8(11.4, 53.3)^ 52 3.1(2.2, 4.5)
Other 5 8.8(2.5, 26.4)^ 130 6.0(4.6, 7.8) 2 4.6(0.63, 26.8)^ 133 6.2(5.0, 7.7)
Concurrent Chi-Squared p-values:*P-Value < .05, **P-Value < .01, ***P-Value < .005; Concordant Chi-Squared p-values:†P-Value <
.05, ††P-Value < .01, †††P-Value < .005. ^ The relative standard error of the weighted prevalence estimate was >30%.
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Table 6: Distribution of Predictors of High Risk Human Papillomavirus Concurrent
and Concordant Infections for Women (U.S. National Health and Nutrition Exami-
nation Survey, 2009-2014)
Concurrent Infection Concordant Infection
Concurrent Infection No Concurrent Infection Concordant Infection No Concordant Infection
Term N Percent(95% CI) N Percent(95% CI) N Percent(95% CI) N Percent(95% CI)
Ethnicity
Other 20 25.2(12.6, 44.3) 2063 24.2(20.9, 27.9) 11 22.2(6.1, 55.4)^ 2072 24.2(20.9, 27.9)
White 21 58.6(35.2, 78.6) 2060 62.9(58.2, 67.3) 15 69.6(36.3, 90.1) 2066 62.8(58.1, 67.3)
Black 10 16.2(6.8, 33.9)^ 1153 12.9(10.7, 15.5) 4 8.3(1.8, 31.2)^ 1159 13.0(10.7, 15.6)
Age Group
18 to 24 15 22.4(13.3, 35.2) 1038 16.7(14.5, 19.1) 11 28.4(12.7, 52.0) 1042 16.7(14.5, 19.1)
25 to 39 16 30.1(16.9, 47.7) 1808 34.3(32.5, 36.0) 7 21.2(6.2, 52.1)^ 1817 34.3(32.6, 36.1)
40 to 59 20 47.5(32.0, 63.5) 2430 49.0(46.4, 51.7) 12 50.4(20.8, 79.8) 2438 49.0(46.3, 51.7)
Marital Status***††
Married 9 18.7(8.1, 37.6)^ 2340 50.3(48.0, 52.6) 7 24.2(8.1, 53.5)^ 2342 50.2(47.9, 52.5)
No longer married 11 28.4(13.8, 49.6) 867 15.7(14.4, 17.1) 6 27.3(6.5, 66.9)^ 872 15.7(14.5, 17.1)
Never married 18 30.4(18.3, 46.1) 1203 20.6(18.4, 23.0) 8 24.4(9.6, 49.6)^ 1213 20.7(18.4, 23.1)
Living with partner 5 10.9(3.7, 28.2)^ 485 9.2(8.2, 10.2) 2 7.4(1.00, 38.8)^ 488 9.2(8.2, 10.3)
Missing 8 11.5(5.0, 24.2)^ 381 4.2(3.6, 5.0) 7 16.7(5.3, 42.0)^ 382 4.2(3.6, 5.0)
Lifetime Sex Partners
0-1 7 7.9(2.7, 21.1)^ 1064 17.8(16.2, 19.5) 6 9.2(2.2, 31.0)^ 1065 17.7(16.1, 19.5)
2-5 14 29.5(10.9, 58.9)^ 1816 35.0(33.3, 36.8) 7 23.0(4.4, 66.0)^ 1823 35.0(33.3, 36.9)
6-10 13 24.2(10.9, 45.6)^ 1046 21.5(19.8, 23.3) 9 28.8(8.2, 64.5)^ 1050 21.5(19.8, 23.2)
11+ 14 33.8(17.1, 55.9) 843 17.9(16.3, 19.7) 8 39.0(12.7, 73.8)^ 849 17.9(16.3, 19.7)
Missing 3 4.5(1.1, 16.5)^ 507 7.8(7.0, 8.7) 0 - 510 7.8(7.0, 8.7)
Recent Sex Partners***†††
0-1 27 53.4(34.8, 71.2) 4024 79.5(77.7, 81.2) 18 53.0(28.1, 76.5) 4033 79.4(77.6, 81.1)
2-5 18 33.1(19.9, 49.7) 685 11.8(10.4, 13.4) 10 35.4(15.7, 61.6) 693 11.8(10.4, 13.4)
6+ 3 9.0(1.5, 38.5)^ 60 0.94(0.68, 1.3) 2 11.6(0.98, 63.7)^ 61 0.95(0.69, 1.3)
Missing 3 4.5(1.1, 16.5)^ 507 7.8(7.0, 8.7) 0 - 510 7.8(7.0, 8.7)
Lifetime Oral Partners**†
0-1 13 20.0(10.7, 34.4) 2080 34.2(32.0, 36.6) 8 13.3(3.9, 37.1)^ 2085 34.2(32.0, 36.5)
2-5 21 39.4(23.0, 58.7) 1986 41.7(39.8, 43.7) 14 47.6(17.1, 80.1) 1993 41.7(39.7, 43.6)
6+ 14 36.1(18.7, 58.1) 706 16.3(14.3, 18.6) 8 39.0(12.7, 73.8)^ 712 16.4(14.4, 18.6)
Missing 3 4.5(1.1, 16.5)^ 504 7.7(6.9, 8.6) 0 - 507 7.8(6.9, 8.7)
Recent Oral Partners***†††
0-1 36 69.3(47.3, 85.0) 4314 84.2(82.8, 85.5) 21 66.0(32.6, 88.7) 4329 84.2(82.8, 85.4)
2-5 9 17.2(7.7, 34.1)^ 417 7.4(6.4, 8.6) 7 22.3(6.6, 53.8)^ 419 7.4(6.4, 8.6)
6+ 3 9.0(1.5, 38.5)^ 41 0.63(0.43, 0.94) 2 11.6(0.98, 63.7)^ 42 0.64(0.44, 0.95)
Missing 3 4.5(1.1, 16.5)^ 504 7.7(6.9, 8.6) 0 - 507 7.8(6.9, 8.7)
HPV Vaccine
Yes 12 16.6(7.7, 32.2)^ 594 10.5(9.2, 12.1) 6 11.1(2.5, 38.2)^ 600 10.6(9.2, 12.1)
No 39 83.4(67.8, 92.3) 4510 87.2(85.5, 88.7) 24 88.9(61.8, 97.5) 4525 87.2(85.5, 88.7)
Missing 0 - 172 2.2(1.8, 2.8) 0 - 172 2.2(1.8, 2.8)
Cigarette Use***†††
Never 21 34.2(18.6, 54.1) 3326 61.3(58.8, 63.8) 10 22.7(8.5, 48.2)^ 3337 61.3(58.8, 63.8)
Ever 25 57.5(33.8, 78.1) 1724 36.2(33.6, 38.8) 16 65.6(30.9, 89.1) 1733 36.2(33.6, 38.8)
Missing 5 8.3(2.9, 21.9)^ 226 2.5(1.9, 3.2) 4 11.6(2.5, 40.3)^ 227 2.5(1.9, 3.2)
Marijuana Use***††
Never 13 22.1(12.5, 36.0) 2498 42.0(39.6, 44.4) 8 20.0(6.9, 45.7)^ 2503 41.9(39.5, 44.4)
Ever 35 73.4(59.3, 84.0) 2273 50.2(47.5, 52.8) 22 80.0(54.3, 93.1) 2286 50.2(47.6, 52.8)
Missing 3 4.5(1.1, 16.5)^ 505 7.9(7.0, 8.7) 0 - 508 7.9(7.1, 8.8)
Sexual Orientation
Heterosexual 42 86.4(72.4, 93.9) 4306 84.7(83.4, 85.9) 26 91.9(70.9, 98.1) 4322 84.7(83.4, 85.9)
Homosexual/Bisexual 4 7.5(2.4, 21.1)^ 289 5.3(4.6, 6.2) 2 5.6(0.82, 30.2)^ 291 5.3(4.6, 6.2)
Other 5 6.1(1.9, 17.3)^ 681 10.0(9.0, 11.1) 2 2.5(0.33, 16.3)^ 684 10.0(9.0, 11.1)
Concurrent Chi-Squared p-values:*P-Value < .05, **P-Value < .01, ***P-Value < .005; Concordant Chi-Squared p-values:†P-Value <
.05, ††P-Value < .01, †††P-Value < .005. ^ The relative standard error of the weighted prevalence estimate was >30%.
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Table 7: Univariable and Adjusted Logistic Models for High Risk Human Papillo-
mavirus Concurrent and Concordant Infections for Combined Population (U.S. Na-
tional Health and Nutrition Examination Survey), 2013-2014 for Men, 2009-2014 for
Women
Concurrent Infection Concordant Infection
Univariate Adjusted Univariate Adjusted
Term OR(95% CI) OR(95% CI) OR(95% CI) OR(95% CI)
Ethnicity
Other Ref Ref Ref Ref
White 2.4(1.3, 4.4)**^ 1.9(0.89, 3.9)^ 2.1(0.92, 5.0)^ 2.0(0.75, 5.2)^
Black 3.0(1.7, 5.1)*** 1.9(0.98, 3.9)^ 2.8(1.1, 7.2)*^ 1.7(0.54, 5.6)^
Gender
Male Ref Ref Ref Ref
Female 0.20(0.12, 0.33)*** 0.25(0.15, 0.42)*** 0.33(0.17, 0.63)*** 0.35(0.16, 0.78)*
Age Group
18 to 24 Ref Ref Ref Ref
25 to 39 1.2(0.70, 2.2)^ 1.1(0.46, 2.4)^ 1.1(0.50, 2.2)^ 1.1(0.37, 3.6)^
40 to 59 1.1(0.52, 2.4)^ 1.1(0.37, 3.3)^ 0.64(0.31, 1.4) 0.73(0.19, 2.9)
Marital Status
Married Ref Ref Ref Ref
No longer married 3.3(1.4, 8.0)**^ 2.1(0.78, 5.5)^ 3.7(1.1, 13.1)*^ 2.2(0.71, 7.0)^
Never married 3.3(1.9, 5.6)*** 2.1(0.94, 4.5)^ 3.5(1.4, 8.7)**^ 1.6(0.44, 6.0)^
Living with partner 3.5(1.4, 8.3)**^ 2.1(0.87, 5.1)^ 2.8(0.80, 9.7)^ 1.3(0.23, 6.9)^
Missing 1.5(0.47, 4.5)^ 2.8(0.57, 14.2)^ 3.0(0.79, 11.7)^ 2.4(0.19, 31.7)^
Lifetime Sex Partners
0-1 Ref Ref Ref Ref
2-5 3.1(0.98, 9.9)^ 3.8(0.94, 15.8)^ 2.8(0.85, 9.5)^ 3.9(0.97, 15.9)^
6-10 6.8(2.7, 17.1)*** 5.5(1.5, 20.7)*^ 4.4(1.6, 12.2)**^ 5.1(1.3, 19.9)*^
11+ 38.3(14.6, 100.4)*** 16.7(4.0, 69.9)*** 20.5(7.4, 57.3)*** 16.1(3.4, 75.5)***
Recent Sex Partners
0-1 Ref Ref Ref Ref
2-5 3.9(2.3, 6.7)*** 1.2(0.35, 4.3)^ 4.5(2.8, 7.3)*** 1.1(0.26, 4.7)^
6+ 4.5(2.2, 9.2)*** 0.45(0.18, 1.1) 6.9(2.8, 17.0)*** 0.55(0.13, 2.4)
Lifetime Oral Partners
0-1 Ref Ref Ref Ref
2-5 1.9(0.87, 4.1)^ 0.66(0.28, 1.6) 1.8(0.59, 5.5)^ 0.61(0.16, 2.3)
6+ 12.5(6.2, 25.0)*** 1.4(0.67, 3.1)^ 7.0(2.8, 17.3)*** 0.68(0.20, 2.3)
Recent Oral Partners
0-1 Ref Ref Ref Ref
2-5 4.3(2.7, 7.0)*** 1.3(0.47, 3.4)^ 5.1(2.6, 9.9)*** 1.8(0.34, 9.5)^
6+ 8.6(3.2, 23.7)*** 2.8(0.69, 11.8)^ 13.3(4.2, 42.3)*** 3.8(0.48, 30.3)^
HPV Vaccine
Yes Ref - Ref -
No 1.5(0.69, 3.4)^ - 1.3(0.48, 3.8)^ -
Missing 0.40(0.08, 1.9) - 0.84(0.17, 4.1) -
Cigarette Use
Never Ref - Ref Ref
Ever 1.8(1.0, 3.3)^ - 2.2(1.2, 4.3)*^ 1.3(0.64, 2.4)^
Missing 1.5(0.50, 4.2)^ - 3.4(1.0, 11.0)^ 3.8(0.52, 27.9)^
Marijuana Use
Never Ref Ref Ref -
Ever 4.1(2.2, 7.7)*** 1.2(0.66, 2.3)^ 2.3(1.0, 5.4)^ -
Sexual Orientation
Heterosexual Ref Ref Ref Ref
Homosexual/Bisexual 4.0(1.9, 8.7)*** 2.1(0.92, 4.6)^ 6.3(2.5, 15.7)*** 3.3(1.0, 10.6)^
Other 0.43(0.08, 2.3) 0.52(0.08, 3.6) 1.1(0.21, 5.8)^ 1.2(0.21, 7.3)^
*P-Value < .05, **P-Value < .01, ***P-Value < .005. ^ The relative standard error of the weighted prevalence
estimate was > 30%.
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Table 8: Univariable and Adjusted Logistic Models for High Risk Human Papillo-
mavirus Concurrent and Concordant Infections for Men (U.S. National Health and
Nutrition Examination Survey, 2013-2014)
Concurrent Infection Concordant Infection
Univariate Adjusted Univariate Adjusted
Term OR(95% CI) OR(95% CI) OR(95% CI) OR(95% CI)
Ethnicitya
Other Ref Ref Ref Ref
White 3.3(1.6, 7.0)**^ 2.8(1.2, 6.5)^ 3.1(0.91, 10.3)^ 2.8(0.72, 10.5)^
Black 4.3(2.0, 8.9)*** 2.2(0.97, 4.8)^ 4.9(1.3, 18.7)*^ 2.6(0.61, 11.5)^
Age Groupa
18 to 24 Ref Ref Ref Ref
25 to 39 1.5(0.74, 2.9)^ 1.1(0.43, 2.7)^ 1.4(0.63, 3.2)^ 1.1(0.30, 4.2)^
40 to 59 1.3(0.49, 3.6)^ 0.97(0.26, 3.7) 0.68(0.22, 2.1) 0.46(0.07, 3.3)
Marital Statusa
Married Ref Ref Ref Ref
No longer married 4.0(1.5, 11.0)*^ 2.4(0.90, 6.4)^ 4.6(0.93, 22.7)^ 2.9(0.61, 14.0)^
Never married 3.0(1.7, 5.5)*** 2.6(1.3, 5.5)*^ 3.7(1.3, 10.3)*^ 2.3(0.45, 11.4)^
Living with partner 3.9(1.4, 10.5)*^ 2.4(0.92, 6.5)^ 3.4(0.85, 13.3)^ 1.5(0.19, 12.1)^
Missing 0.65(0.10, 4.4) 1.5(0.12, 18.3)^ 1.4(0.13, 16.4)^ 1.8(0.05, 65.5)^
Lifetime Sex Partnersa
0-5 Ref Ref Ref Ref
6-10 5.6(2.0, 15.5)**^ 5.0(1.7, 14.6)*^ 1.8(0.49, 6.4)^ 1.6(0.44, 6.1)^
11+ 34.1(11.2, 104.1)*** 27.8(7.8, 98.9)*** 12.2(3.7, 40.1)*** 11.1(2.6, 46.6)*^
Recent Sex Partnersb
0-1 Ref Ref Ref Ref
2-5 3.5(1.9, 6.5)*** 2.6(1.2, 5.6)^ 4.1(2.4, 7.0)*** 2.7(1.3, 5.6)*^
6+ 2.6(1.2, 5.4)*^ 1.7(0.78, 3.7)^ 4.1(1.5, 11.0)*^ 2.5(0.90, 7.0)^
Lifetime Oral Partnersb
0-1 Ref Ref Ref Ref
2-5 2.0(0.60, 6.8)^ 1.8(0.43, 7.6)^ 1.4(0.26, 7.1)^ 1.3(0.17, 9.8)^
6+ 14.3(5.5, 37.2)*** 10.8(3.3, 34.9)* 5.8(1.9, 17.9)**^ 4.7(1.1, 21.0)^
Recent Oral Partnersb
0-1 Ref Ref Ref Ref
2-5 4.1(2.3, 7.3)*** 2.8(1.6, 4.9)* 4.9(2.2, 11.2)*** 3.3(1.3, 8.0)^
6+ 6.0(1.8, 19.5)*^ 3.6(0.90, 14.2)^ 9.4(2.3, 38.2)**^ 5.1(1.1, 23.2)^
HPV Vaccineb
Yes Ref - Ref -
No 1.5(0.40, 5.9)^ - 1.0(0.21, 5.1)^ -
Missing 0.31(0.05, 2.1) - 0.55(0.07, 4.1) -
Cigarette Useb
Never Ref - Ref -
Ever 1.5(0.74, 2.9)^ - 1.7(0.75, 3.6)^ -
Marijuana Useb
Never Ref Ref Ref -
Ever 3.8(1.8, 8.3)*** 2.8(1.3, 6.1)*^ 1.8(0.66, 4.7)^ -
Sexual Orientationb
Heterosexual Ref Ref Ref Ref
Homosexual/Bisexual 6.6(2.7, 16.1)*** 4.2(1.6, 11.2)*^ 11.9(4.2, 34.3)*** 8.5(2.6, 27.2)*
Other 0.42(0.04, 5.0) 0.37(0.03, 4.4) 1.3(0.11, 14.4)^ 1.3(0.11, 13.8)^
1 *P-Value < .05, **P-Value < .01, ***P-Value < .005. ^ The relative standard error of the weighted prevalence
estimate was > 30%.
a Adjusted model included ethnicity, age group, marital status, and lifetime number of sex partners.
b Adjusted model included ethnicity, age group, marital status, and the covariate of interest.
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Table 9: Univariable and Adjusted Logistic Models for High Risk Human Papillo-
mavirus Concurrent and Concordant Infections for Women (U.S. National Health
and Nutrition Examination Survey, 2009-2014)
Concurrent Infection Concordant Infection
Univariate Adjusted Univariate Adjusted
Term OR(95% CI) OR(95% CI) OR(95% CI) OR(95% CI)
Ethnicity
Other Ref Ref Ref Ref
White 0.87(0.36, 2.1) 0.63(0.21, 1.9) 1.1(0.37, 3.2)^ 0.73(0.22, 2.5)
Black 1.3(0.62, 2.7)^ 0.86(0.40, 1.8) 0.67(0.19, 2.3) 0.47(0.14, 1.6)
Age Group
18 to 24 Ref Ref Ref Ref
25 to 39 0.65(0.32, 1.3) 1.5(0.43, 5.1)^ 0.38(0.16, 0.89)* 0.88(0.15, 5.2)
40 to 59 0.69(0.38, 1.2) 2.1(0.75, 5.9)^ 0.61(0.24, 1.5) 1.9(0.48, 7.6)^
Marital Status
Married Ref Ref Ref Ref
No longer married 4.5(1.5, 13.5)**^ 2.5(0.73, 8.5)^ 3.5(1.0, 12.5)^ 1.7(0.48, 6.0)^
Never married 3.8(1.6, 9.1)**^ 2.8(0.79, 9.6)^ 2.4(0.84, 7.0)^ 1.8(0.39, 8.0)^
Living with partner 2.7(0.86, 8.3)^ 2.0(0.62, 6.4)^ 1.7(0.34, 8.3)^ 1.2(0.28, 5.5)^
Missing 7.1(2.4, 20.7)*** 5.9(1.0, 34.4)^ 8.0(2.5, 25.4)*** 6.5(0.95, 44.8)^
Lifetime Sex Partners
0-1 Ref Ref Ref Ref
2-5 1.9(0.47, 7.3)^ 0.99(0.14, 7.1) 1.2(0.23, 6.5)^ 0.36(0.06, 2.2)
6-10 2.5(0.89, 6.9)^ 0.70(0.16, 3.1) 2.5(0.81, 7.8)^ 0.41(0.09, 1.8)
11+ 4.1(1.5, 11.6)**^ 0.57(0.11, 3.0) 4.1(1.3, 13.3)*^ 0.36(0.08, 1.7)
Recent Sex Partners
0-1 Ref Ref Ref Ref
2-5 4.2(2.2, 7.8)*** 3.3(0.87, 12.8)^ 4.4(2.1, 9.3)*** 3.2(0.45, 23.2)^
6+ 14.1(2.6, 75.9)***^ 4.2(0.85, 20.3)^ 18.2(2.8, 120.2)***^ 4.6(0.55, 38.9)^
Lifetime Oral Partners
0-1 Ref Ref Ref Ref
2-5 1.6(0.81, 3.1)^ 1.3(0.44, 3.8)^ 2.9(0.96, 8.7)^ 3.0(0.75, 12.0)^
6+ 3.7(1.5, 9.2)**^ 2.1(0.47, 9.6)^ 6.0(1.9, 18.6)***^ 3.1(0.54, 18.1)^
Recent Oral Partners
0-1 Ref Ref Ref Ref
2-5 2.8(1.2, 6.3)*^ 0.65(0.13, 3.2) 3.8(1.4, 10.4)*^ 0.95(0.11, 8.0)
6+ 16.8(3.1, 92.5)***^ 2.6(0.54, 12.5)^ 22.5(3.2, 155.8)***^ 3.3(0.41, 26.8)^
HPV Vaccine
Yes Ref - Ref -
No 0.59(0.28, 1.2) - 0.99(0.33, 3.0) -
Cigarette Use
Never Ref Ref Ref Ref
Ever 3.2(1.3, 7.9)*^ 2.3(0.81, 6.5)^ 4.8(1.8, 12.6)***^ 3.3(1.3, 8.1)*^
Missing 6.6(3.3, 13.2)*** 1.8(0.31, 11.1)^ 12.0(5.3, 27.1)*** 1.9(0.27, 13.1)^
Marijuana Use
Never Ref Ref Ref Ref
Ever 2.7(1.5, 4.9)*** 1.7(0.89, 3.1)^ 3.3(1.4, 7.9)*^ 1.4(0.70, 2.9)^
Sexual Orientation
Heterosexual Ref - Ref -
Homosexual/Bisexual 1.4(0.48, 4.0)^ - 0.98(0.24, 4.0) -
Other 0.69(0.16, 3.0) - 1.0(0.24, 4.6)^ -
*P-Value < .05, **P-Value < .01, ***P-Value < .005. ^ The relative standard error of the weighted prevalence
estimate was > 30%.
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Figure 1: Histograms of Simulated Proportions of High Risk Human Papillomavirus
Concurrent Infection for Combined Population (U.S. National Health and Nutrition
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Figure 2: Histograms of Simulated Proportions of High Risk Human Papillomavirus












Men HR Concurrent Infections












Men HR 9V Vaccine Concurrent Infections













Men HPV 16, 18, or 45 Concurrent Infections











Men HPV 16 Concurrent Infections
Mean = 0.0008; Simulated p−value = 0.0004; 95% CI of simulated proportions: (0.0003, 0.0014)
48
Figure 3: Histograms of Simulated Proportions of High Risk Human Papillomavirus
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Figure 4: Histograms of Simulated Proportions of High Risk Human Papillomavirus
Concordant Infection for Combined Population (U.S. National Health and Nutrition
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Figure 5: Histograms of Simulated Proportions of High Risk Human Papillomavirus
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Figure 6: Histograms of Simulated Proportions of High Risk Human Papillomavirus
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